

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK

	1
Journal:	BMJ Open
Manuscript ID	bmjopen-2021-060506
Article Type:	Original research
Date Submitted by the Author:	07-Jan-2022
Complete List of Authors:	Payne, Heather; University College London Hospitals NHS Foundation Trust, Consultant Clinical Oncologist Jain, Suneil; Queen's University Belfast, School of Medicine, Dentistry and Biomedical Sciences Peedell, Clive; James Cook University Hospital, Department of Radiotherapy and Oncology Edwards, Albert; Kent Oncology Centre Thomas, James Andrew; Princess of Wales Hospital, Department of Urology Das, Prantik; University Hospitals of Derby and Burton NHS Foundation Trust, Department of Oncology Hansson Hedblom, Amanda; Coreva Scientific GmbH und Co KG Woodward, Emily; Boston Scientific AG Saunders, Rhodri; Coreva Scientific GmbH und Co KG Bahl, Amit; University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre
Keywords:	Prostate disease < UROLOGY, Radiation oncology < RADIOLOGY & IMAGING, RADIOTHERAPY, Toxicity < THERAPEUTICS
	·

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

1 Title page

Delphi study to identify consensus on patient selection for
hydrogel rectal spacer use during radiation therapy for prostate
cancer in the UK.

Short title: Delphi study on hydrogel rectal spacer use (UK)

Authors: Heather Ann Payne¹, Suneil Jain², Clive Peedell³, Albert Edwards⁴, James Andrew
Thomas⁵, Prantik Das⁶, Amanda Hansson Hedblom⁷, Emily Woodward⁸, ^{IM} Rhodri Saunders⁷,

8 Amit Bahl⁹

Institutional affiliations: ¹Consultant Clinical Oncologist, University College London Hospitals NHS Foundation Trust, London, United Kingdom; ²School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom; 3Department of Radiotherapy and Oncology, James Cook University Hospital, Middlesbrough, United Kingdom; ⁴Kent Oncology Centre, Kent, United Kingdom; ⁵Department of Urology, Princess of Wales Hospital, Bridgend, United Kingdom; ⁶Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom; 7Coreva Scientific, Königswinter, Germany; ⁸Boston Scientific AG, Solothurn, Switzerland; ⁹Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, United Kingdom

Corresponding author:

19 Rhodri Saunders, Coreva Scientific GmbH & Co KG, Im Mühlenbruch 1, 53639 Königswinter,
20 North Rhine-Westphalia, Germany. rhodri@coreva-scientific.com

21 Word count: 3,971

BMJ Open

2 3 4	22	Delphi study to identify consensus on patient selection for						
5 6 7 8	23	hydrogel rectal spacer use during radiation therapy for prostate						
9 10 11	24	cancer in the UK.						
12 13 14 15	25	Structured abstract (Word count: 268, max 300)						
16 17	26	OBJECTIVES						
18 19 20	27	To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation						
21 22	28	therapy for the treatment of prostate cancer in the United Kingdom.						
23 24 25	29	DESIGN						
26 27	30	Delphi study consisting of two rounds of online questionnaires, two virtual advisory board						
28 29	31	meetings and a final online questionnaire.						
30 31 32	32	SETTING						
33 34 35	33	Radical radiation therapy for localised and locally advanced prostate cancer in the United						
36 37	5 34 Kingdom.							
38 39 40	35	PARTICIPANTS						
41 42	36	Six leading clinical oncologists and one urologist from across the UK.						
43 44 45	37	INTERVENTIONS						
46 47	38	Rectal hydrogel spacer.						
48 49 50	 39 PRIMARY AND SECONDARY OUTCOME MEASURES 40 NR 							
51 52 53								
54 55	41	RESULTS						
56 57 58	42	The panel reached consensus on the importance of minimizing toxicity for treatments with						
59 60	43	curative intent, and that even low-grade toxicity-related adverse events can significantly						

Page 2 of 23

impact quality of life. There was agreement that despite meeting rectal dose constraints, too many patients experience rectal toxicity, and that rectal hydrogel spacers in eligible patients significantly reduces toxicity related adverse events. However, as a consequence of funding limitations, patients need to be prioritized for spacer use. A higher benefit of spacers can be expected in patients on anticoagulation, and in patients with diabetes or inflammatory bowel disease, but consensus could not be reached regarding patient groups expected to benefit less. While radiation therapy regimen is not a main factor determining prioritization, higher benefit is expected in ultra-hypofractionated regimens.

52 CONCLUSION

53 There is a strong and general agreement that all prostate cancer patients undergoing radical 54 radiation therapy have the potential to benefit from hydrogel spacers. Currently, not all patients 55 who could potentially benefit can access hydrogel spacers, and access is unequal. 56 Implementation of the consensus recommendations would likely help prioritise and equalise 57 access to rectal spacers for patients in the UK.

Page 3 of 23

1 2		
3 4	58	ARTICLE SUMMARY: STRENGTHS AND LIMITATIONS OF THIS STUDY
5 6 7	59	• The Delphi panel is a recognised method in developing NICE guidelines and is utilised
7 8 9	60	here to gather insights from a diverse panel of UK radiation oncology and urology
) 10 11	61	experts who are experienced users of hydrogel spacers.
12 13	62	• This study included seven panel experts and their experiences may not reflect all users
14 15	63	of hydrogel spacers.
16 17	64	• To help reduce bias, answers and opinions were assessed by two researchers working
18 19 20	65	independently.
21 22	66	WHAT IS ALREADY KNOWN ON THIS TOPIC?
23 24	67	• Radiation toxicity to nearby healthy tissue is a potential problem when undertaking
25 26 27	68	radical radiotherapy with curative intent for prostate cancer.
27 28 29	69	• Biodegradable spacers are used to separate the prostate and the rectum, thus
30 31	70	reducing radiation exposure to a primary dose-limiting organ.
32 33	71	• Spacer funding and capacity are limited and there is a need to understand which
34 35	72	patients to prioritise for use of a spacer.
36 37	73	WHAT DOES THIS STUDY ADD?
38 39 40	74	• Expert consensus opinion can help to guide strategy in areas of care where the
41 42	75	evidence base is lacking.
43 44	76	 There was consensus that increased benefit from spacers is expected in patients on
45 46	77	anticoagulation and/or with diabetes and/or inflammatory bowel disease.
47 48		
49 50		
51		
52 53		
54		
55		
56		
57 58		
58 59		
60		

78 INTRODUCTION

79 Prostate cancer burden

Prostate cancer is the second most common cancer in men globally,¹ and the most common in the UK.² More than 47,500 UK men are diagnosed with prostate cancer every year and over 400,000 men are living with and after prostate cancer.³ The 5-year survival rate for localized prostate cancer in the UK is almost 100%,⁴ with three guarters of men diagnosed at any stage expected to survive 10 years.² In England, 97%, 87% and 78% of men diagnosed with prostate cancer survive their disease for more than one, five and ten years, respectively.² Given the high likelihood of curative therapy, a key treatment goal is to prevent potential adverse events from impacting patient quality of life after treatment.

In addition to the patient burden, prostate cancer is a costly disease with the European costs
of care for prostate cancer estimated at EUR 199 billion in 2018.⁵

90 Radiation therapy for prostate cancer

Choice of treatment for prostate cancer is complex and involves multi-factorial considerations including presenting cancer stage (localised, locally advanced or metastatic), risk stratification, life expectancy, comorbidities, and other patient-specific factors, such as lifestyle, patient preference and treatment goals.⁶ For localised and locally advanced prostate cancer, treatment options include active surveillance, surgery, and radiation therapy (RT), with or without hormone treatment, as well as multimodality treatment combining surgery or RT with systemic therapy.⁷⁻⁹ RT with radical intent is a first-line treatment for localised and locally advanced prostate cancer.8 Intensity-modulated RT (IMRT) with image guidance (IGRT) is considered the gold-standard form of external beam RT (EBRT).¹⁰ Of the circa 18,000 men identified as having received radical RT for prostate cancer in England and Wales between April 2018 and March 2019, over 90% were treated with IMRT.¹¹ Whilst stereotactic body RT (SBRT) is not currently routine practice in the UK, its use is increasing and it is now delivered

BMJ Open

in several NHS centres.¹² Circa 95% of UK men with intermediate-risk disease receive a hypofractionated radiotherapy regimen.¹¹

The success and clinical outcomes of RT depend on several factors, including radiation dose to the tumour and the extent of irradiation affecting nearby normal-tissue, particularly the rectum.¹⁰ Dose-escalated EBRT is a highly effective curative treatment, with higher doses providing better biochemical control.¹³ Higher doses can, however, increase radiation toxicity to nearby tissues. Despite substantial advancements in RT, acute and reversible, as well as rare but severe, long-term adverse effects of radiation toxicity such as urinary and bowel incontinence remain problematic. In 2021, The National Prostate Cancer Audit (NPCA) reported that 11% of prostate cancer patients experienced ≥1 severe gastrointestinal complication (defined as a confirmed diagnosis of radiation toxicity and requiring a procedure to the large bowel) within two years after radical RT.¹¹ Due to its proximity to the prostate, the anterior rectal wall is especially vulnerable to irradiation effects and the rectum is a doseerie limiting organ at risk.¹⁴

Hydrogel spacers

One way of reducing the unwanted radiation dose to the rectum is by increasing the space between the prostate and the rectal wall. This can be achieved by use of a rectal spacer, with three currently indicated for use during RT for prostate cancer in the UK: biodegradable balloons, hyaluronic acid gel, and polyethylene glycol (PEG) hydrogel.¹⁵ In the UK, the use of biodegradable spacers to reduce rectal toxicity during RT for prostate cancer is accepted (IPG590) by NICE, based on safety and efficacy data on the use of PEG hydrogel spacers.¹⁵ Use of rectal hydrogel spacers has been evaluated in a single-blind, phase III trial in image guided IMRT (N=222).¹⁶ The spacer-placement success rate was 99%, and no device-related adverse events occurred.¹⁶ Late (three to 15 months) rectal toxicity severity was significantly reduced in the spacer group.¹⁶ At three years follow-up, decreased bowel toxicity and fewer declines in urinary and bowel quality of life were observed in the spacer group.¹⁷

Page 6 of 23

> Lack of routine reimbursement has led to restricted patient access to hydrogel spacers in the UK. Therefore, there is a requirement to prioritise patients for hydrogel spacer use in the UK, and attempts have been made to identify optimal usage. A secondary analysis of the hydrogel spacer trial data tried to identify the patient subgroups most and least likely to benefit from the intervention but found generally homogeneous results in bowel quality of life with benefits in all assessed subgroups.¹⁸

The aim of this study was to identify consensus on patient prioritisation for rectal hydrogelspacer use during RT for the treatment of prostate cancer in the UK.

137 METHODS

138 The Delphi technique and panel experts

The Delphi technique is a structured, iterative, multistage process using rounds of questionnaires to collect opinions and to stepwise develop consensus among a pre-defined panel of experts.¹⁹ For this study, experts were approached and asked to participate in the panel based on being a UK radiation oncologist or urologist having experience with rectal hydrogel spacers. To ensure a diverse panel, experts were sought to represent different geographies within the UK and use different types of RT modalities. There is no defined optimal panel size for a Delphi study,²⁰ but the selection of an odd number of experts ensured that a majority outcome could be reached.

147 Steps in the Delphi process

148 There is no fixed number of rounds in a Delphi survey.²⁰ As depicted in Figure 1, our study
 149 adopted a five-stage approach to elicit consensus, consisting of two pre-advisory board
 150 questionnaires administered through a web-based survey program, two virtual advisory board
 151 discussions, and a final concluding questionnaire.

The first questionnaire provided some background information on the experts, such as their
 most used RT modalities and open-ended questions to capture a broad understanding. The

Page 7 of 23

BMJ Open

 154 open-ended questions related to key treatment aims, which patient and treatment 155 characteristics to consider when prioritising hydrogel spacer, factors typically deterring them 156 from recommending hydrogel spacer use, and factors predictive for toxicity. Additionally, 157 experts were asked to rank treatment modalities in order of how much patient benefit they 158 would expect from hydrogel spacer use, on a scale from 0 (no patient benefit) to 100 (maximal 159 patient benefit).

160 In the second questionnaire, the responses to the open-ended questions from the previous 161 questionnaire were presented, and the experts asked to rank them by order of importance. In 162 addition to follow-up questions, the second questionnaire included questions on perceived 163 barriers to hydrogel spacer use.

164 Figure 1: Overview of Delphi panel process

165 Analysis and scoring

Qualitative content analysis was used to analyse responses to open-ended questions. Two researchers independently analysed responses and interpreted consensus. At the advisory board meetings, results from the questionnaires were presented together with initial drafted consensus statements for discussion. Then followed moderated discussions which led to revisions of the consensus statements. In the final online questionnaire, the consensus statements were presented, and the experts asked to select a level of agreement: "I fully agree", "I partially agree" or "I disagree". Upon selecting "I partially agree", experts were asked to give a comment and/or update the wording of the statement. The responses were linked to an agreement score, based on the answer selected, and the comment given if "I partially agree" was selected (Table 1).

176 Table 1: Consensus statement scoring key

Score	Answer selected	Description
4	"I fully agree"	
3	"I partially agree"	With minor word change
2	"I partially agree"	With minor change to statement interpretation/meaning
1	"I disagree"	

Page 8 of 23

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Consensus definitions vary between studies²¹⁻²⁵, with percent agreement being one of the more common approaches.²⁵ Based on the results of our final online survey, statements were categorised into four levels of consensus (strong, moderate, low, and no consensus). This study scored the level of consensus in terms of percent agreement, and additionally that consensus could not be reached in case any expert disagreed with a statement. Figure 2 depicts the consensus statement scoring for this study. Only statements grouped as either Strong or Moderate are considered statements where consensus was reached. Weak or No consensus mean that there was still substantial discussion or divergence of opinion among

20 185 the experts. 21

23 186 Figure 2

Figure 2: Consensus statement scoring, decision tree

25 187 Consent, privacy, and data security

The panel experts were informed about and consented to the full Delphi process, including length and time of surveys and details on the data collected, stored, and deleted. The retention periods of collected data were pre-defined. Questionnaire responses were anonymised and securely stored on the survey software provider's server in Germany. Audio recordings were stored for 60 days on the conference provider's EU based server. All experts were contracted for this study and reimbursed at fair, local market rates for their time commitment during the Delphi process. The study was approved by an independent review board (HML IRB Review #952SCGC21).

46 196 Patient and public involvement

- 49 197 No patients involved.50
- 52 198 **RESULTS**

55 199 Panel expert characteristics

All approached experts agreed to participate (N=7). Details on the panel experts' treatment
 practices are presented in Table 2. The majority of the panel (N=6) exclusively use rectal

Page 9 of 23

- 202 hydrogel spacers in their practices. One uses rectal hydrogel spacers as well as biodegradable
 - 203 balloons. Participation rates were high, with only one dropout (one expert did not complete the
 - 204 second questionnaire but participated in all other steps).

205 Table 2: Panel experts treatment practice

Geographical setting, N (%)			
England	5 (57)		
Northern Ireland	1 (14)		
Wales	1 (14)		
Public or private setting, N (%)	·		
Public only	1 (14)		
Private only	0 (0)		
Both	6 (86)		
Most frequently used RT modalities, % of patients (N experts using modality)			
IMRT	25–95 (6)		
EBRT (not specified)	90 (1)		
IMRT and HDR BT boost	15–30 (2)		
SBRT	45 (1)		
BT monotherapy (LDR)	10–20 (2)		
PBT	10 (1)		

Key: IMRT, intensity-modulated radiation therapy; EBRT, external beam radiation therapy; HDR, high dose rate;
 BT, brachytherapy; SBRT, stereotactic body radiation therapy; LDR, low dose rate; PBT, proton beam therapy.

208 Key treatment aims, besides curing or controlling cancer and increasing overall survival, were

36 209 to minimise the risk of side effects and toxicity.

210 Questionnaire outcomes shaping the consensus statement discussion

Questionnaire outcomes showed that the panel estimated considerably less toxicity in patients
with hydrogel spacer, as compared to those without (Figure 3). All experts agreed that
hydrogel spacers reduce grade 1 and 2 late rectal toxicity, 86% agreed that it reduces grade
3 toxicity and 71% grade 4 toxicity.

- 52 215 Figure 3: Expected level of late (after 3 months) rectal toxicity in patients with and without hydrogel spacer 53
- 54 216 The panel considered toxicity a considerable issue, and underlined that also low-grade
- 56 217 toxicity-related adverse events may significantly worsen patient's lives:

'I ask them [my patients], when you're out and about, is the first thing you think of where
the toilet is?... And a remarkable number of patients say yes to that question, and it is
affecting their quality of life.'

In the first questionnaire, the panel estimated that an average of 83% (SD: 13%) patients who
could potentially benefit from a hydrogel spacer were denied access. Throughout the
discussions, patient access in general and equal access in particular were central themes.
The panel voiced their concern, for example regarding differences between NHS and private
practice:

'In my private practice, every patient gets it [hydrogel spacer] unless there is a reason
why they should not get it. Whereas in my NHS practice, unfortunately no patient gets
it, unless there is a reason why they should get it.'

The main barrier to hydrogel spacer use was funding and resource constraints, followed bylack of trained staff.

231 'The ideal way to go would be to offer it to every eligible patient. But given that this is
232 not currently feasible in our centre, there has to be some kind of categorisation.'

As seen in Figure 4, a trend towards hypo-fractionated external-beam regimens, with potential increased bowel dose and toxicity being associated with more potential benefit for spacers was apparent. This was also reflected in the outcome of the conjoint analysis. The absolute variation between expected benefit was, however, relatively low, ranging from 67 (BT monotherapy LDR) to 80 (SBRT/SABR) on average. This was reflected in later discussions, where experts agreed that RT modality is not the main consideration when prioritising patients for hydrogel spacer use.

240 Figure 4: Expected patient benefit from hydrogel spacer use, by treatment modality

When asked about patient characteristics to consider when deciding whether to recommend
 using hydrogel spacer the experts gave a wide range of suggestions, including comorbidities
 (age, diabetes, high bleeding risk, hip prothesis, inflammatory bowel disease and rectal and

Page 13 of 27

1 2

60

BMJ Open

2							
3 4	244	bowel problems, normal erectile function), cancer stage, localisation, and heavy smoking. This					
5 6	245	was narrowed down in subsequent discussion, with general agreement that patients with					
7 8	246	certain comorbidities (diabetes, inflammatory bowel disease) or on anticoagulation may					
9 10	247	higher benefit from hydrogel spacers.					
11 12 13 14 15	248	Consensus statements					
16 17	249	Upon being shown the results of the questionnaires, two rounds of moderated discussion					
18 19	250	followed, resulting in 13 consensus statements. These statements were subsequently voted					
20 21	251	on in a final questionnaire, and a final scoring was assigned as described in the method					
22 23 24	252	section.					
25 26	253	The following eight statements reached strong consensus:					
27 28							
29 30	254	• Our consensus opinion is that for treatments with curative intent, focus should be on					
31 32	255	minimising toxicity and the risk of side effects.					
33 34	256	Our consensus opinion is that use of spacers in eligible patients significantly reduces					
35 36	257	radiation dose to the rectum and toxicity-related adverse events.					
37 38	258	• Our consensus opinion is that despite meeting rectal dose constraints, too many					
39 40	259	patients continue to experience rectal toxicity.					
41 42	260	• Our consensus opinion is that certain grade 1 toxicity-related adverse events ¹ can still					
43 44	261	have a significant impact on patient quality of life.					
45 46	262	• Our consensus opinion is that any toxicity grading system in use should be					
47 48	263	complemented by patient-reported outcomes.					
49 50							
51 52							
52 53							
54 55							
55 56							
57							
58 59		¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal					
60		bower requercy and digency, diarnoca, naturence, radiation cystills, radiation proclitis, rectai					

¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal bleeding, rectal mucus.

Page 14 of 27

BMJ Open

1

59 60

1		
3 4	264	Our consensus opinion is that patients receiving long-term anticoagulation therapy with
5 6	265	medications such as direct oral anticoagulants (DOACs) ² should be considered for
7 8	266	spacer use if their anticoagulation can be safely paused.
9 10	267	• Our consensus opinion is that spacers are useful in eligible patients with T1-T2
11 12	268	disease. Spacer use in patients with T2+ disease should not be excluded but should
13 14	269	be assessed on an individual basis by a team proficient in inserting spacers.
15 16	270	• Our consensus opinion is that patients should have the opportunity to take part in the
17 18 19	271	discussion regarding the use of a spacer. ²⁶
20		
21 22	272	For the following two statements, moderate consensus was reached. Each statement is
23 24	273	followed by an explanation on why strong consensus was not reached.
25 26	274	• Our consensus opinion is that a higher benefit of spacers is expected in eligible
20 27	274	• Our consensus opinion is that a higher benefit or spacers is expected in engible
28 29	275	patients with certain comorbidities ³ and/or longer expected overall survival.
30 31	276	Six experts (86%) fully agreed with the statement. One expert (14%) only partially agreed and
32 33	277	suggested removing "and/or longer expected overall survival". This was deemed a change to
34 35	278	the statement interpretation.
36 37		
38 39	279	• All eligible radiotherapy patients should have equal opportunity to access spacers,
40 41	280	independent of socio-economic factors.
42 43	281	Five experts (71%) fully agreed with the statement. While there was an overall agreement that
44	282	lack of equality in access to spacers is currently an important issue, two experts (29%) had
45 46	202	lack of equality in access to spacers is currently an important issue, two experts (29%) had
47 48	283	rewording suggestions that would have impacted the statement interpretation. One proposed
49 50	284	to add more detail on eligibility, and to add that patients suitable for a spacer implant should
51 52	285	have access, irrespective of whether they can afford it. The other expert expressed some
53		
54 55		
56 57		
57 58 50		² The reason for prescribing the DOAC, rather than the medication itself, is more important for the decision. All patients on DOACs, except for cardiac stent and prosthetic valve replacement patients

decision. All patients on DOACs, except for cardiac stent and prosthetic valve replacement patients may be able to safely pause their anticoagulation.

³ Anticoagulation, diabetes, inflammatory bowel disease (ulcerative colitis and Crohn's disease)

1 2		
3 4	286	uncertainty regarding the term "socio-economic factors" and would have preferred the wording
5 6 7	287	"irrespective of post-code".
8 9 10	288	Statements where no consensus was reached
11 12 13	289	One statement was categorised as a weak consensus statement:
14 15	290	• Whilst we support the use of spacers in all eligible patients, our consensus opinion is
16 17	291	that if resource constraints exist, patients receiving ultra-hypofractionated or
18 19 20	292	hypofractionated radiotherapy should be prioritised for access to a spacer.
21 22	293	Four experts (57%) fully agreed with the statement. The remaining three (43%) partially
23 24	294	agreed but had additional comments. One expert expressed that individual risk factors should
25 26	295	be considered, rather than the RT modality. The second expert agreed on the need to identify
27 28 29 30 31 32 33 34 35 36 37 38	296	a group at higher risk of rectal toxicity, and suggested combination of RT modality
	297	considerations and patient characteristics (e.g., age) and comorbidities. The third respondent
	298	only agreed that patients receiving ultra-hypofractionated RT should be prioritised.
	299	For the following two statements, no consensus was reached.
	300	• Our consensus opinion is that for patients with anticipated short overall survival but
39 40	301	who will receive radical radiotherapy, use of a spacer should only be considered after
41 42 43	302	careful evaluation of potential benefit.
44 45	303	Three experts (43%) fully agreed. Four (57%) partially agreed but had additional comments.
46 47	304	Two experts made the point that it is unlikely that patients with short anticipated overall survival
48 49	305	would be indicated for radical radiotherapy. Two experts expressed uncertainty with the
50 51	306	wording "overall survival". One of them suggested a rewording that some carefully selected
52 53 54	307	patients with short expected survival who are offered radical radiotherapy may benefit from
55 56	308	spacer use after careful consideration. The second expressed that the statement was too
57 58	309	unclear. Additionally, in subsequent discussions, the experts agreed that the term "anticipated
59 60	310	shorter life expectancy" would have been preferred over "anticipated short overall survival",

Page 14 of 23

so as not to imply that the use of hydrogel spacers affects survival. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement.

Our consensus opinion is that there are a limited number of patients with risk factors, or combination of risk factors, in which use of a spacer should only be considered after careful evaluation of potential benefits.

Four experts (57%) fully agreed, two (29%) partially agreed, and one (14%) disagreed. Those who partially agreed expressed that an addition should be made to the statement, that the majority of patients who receive radical RT would also be suitable for a spacer, noting that patients who are not fit enough for a spacer, likely are also not fit for RT. The second partially agreeing expert wanted to add a recommendation to discuss such cases with a mentor with extensive experience in spacer insertion. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement. Lien

DISCUSSION

Statement of principal findings

There was strong consensus that rectal toxicity is a considerable issue, and that minimizing the risk of radiation side effects is an important treatment aim. Rectal hydrogel spacers can reduce the toxicity burden and benefit patients undergoing radical RT for the treatment of prostate cancer in the UK. Currently, the NHS does not routinely fund hydrogel spacers. Limited funding leads to limited resources, and therefore limited access. Experts estimated that on average, 83% of their patients that could benefit from a spacer are not currently getting access. There was moderate consensus that a higher benefit is expected in patients on anticoagulation, patients with diabetes, and patients with inflammatory bowel disease (Ulcerative colitis or Crohn's disease). However, experts expected the majority of patients to benefit from use of a spacer, and it was not possible to reach consensus on those patients

Page 15 of 23

Page 17 of 27

1 2

BMJ Open

3	
4	
5	
6	
7	
8	
9	
10	
11	
12 13	
14	
15	
16 17	
18	
19	
20	
21	
22	
23	
24	
25	
26 27	
27 28	
20 29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56 57	
57 58	
20	

with lower expected benefit. Key takeaways from discussions around statements where no
consensus was reached are that individual patient characteristics are more important for
informing the decision on whether to prioritise the use a spacer than the RT regimen selected.
However, a higher level of benefit from spacer use is expected with ultra-hypofractionated RT
compared with standard RT, a conclusion in line with current clinical evidence.²⁷

342 **Me**

Meaning of the study: possible explanations and implications for clinicians and policy

343 makers

344 Currently, patient selection is driven by limitations in the healthcare system rather than patient 345 needs. This highlights the importance of developing guidance on spacer use, to ensure fair 346 and equal access to healthcare. The COVID-19 pandemic has lengthened already substantial 347 NHS waiting times, further exacerbating issues with access and underscoring the need for formal guidance. Additionally, practical issues (e.g., availability of trained staff, theatre 348 349 capacity) need to be considered when preparing a clinic to start using hydrogel spacers. As is 350 important for all techniques to be introduced, audit of practice and quality improvement is 351 recommended.

352 Strengths and weaknesses

This study only included seven experts, who are all experienced users of hydrogel spacers Naturally, a broader selection of experts could have resulted in different answers. However, including non-users as panel experts would not have been feasible for the purposes of this study, as they would have not possessed the relevant experience required. Additionally, the RT modality used by panel members could influence their view on when to prioritise hydrogel spacer use. However, the diversity of the panel in terms of modalities used likely safeguarded the balance of the resulting consensus.

The main strengths of this study are the scientific rigour applied following a well-defined and
 proven Delphi methodology, and the experience and diversity of the panel. The Delphi method

allowed gathering insights from leading experts in the field from different UK countries utilising
a mix of RT modalities, while reducing bias and separating the evaluation by tasking two
independent researchers with analysis and scoring.

365 Comparison with other studies

To the best of our knowledge, no previous attempts have been done to establish consensus for rectal hydrogel spacer use in the UK. One study conducted secondary analyses of a singleblinded, phase III randomised trial, with the aim of identifying patients benefitting the least from hydrogel rectal spacer during prostate radiation therapy.¹⁸ In line with this study, no subgroup without potential benefits of hydrogel spacers could be identified. The benefit of hydrogel spacers perceived by the experts is in line with current clinical evidence.¹⁷

372 Unanswered questions and future research

This study offers guidance to later adopters of rectal hydrogel spacers, building on the expertise of leading UK radiation oncologists and urologist. Future research should focus on implementing formal guidance on hydrogel spacer use and strive towards reaching a consensus on patient prioritisation. A larger follow-up consensus study would be of value, asking all UK domain experts their opinion on the consensus statements. With growing interest in hydrogel spacers, it is increasingly important to study the impact of the guality of the implant. There is an ongoing debate on what a good implant is, and how it is measured. Similarly, it would be valuable to reach an agreement on which toxicity data to generate and follow up through including hydrogel spacers in cancer treatment trials, or through the development of a quality registry. Finally, it is of utmost importance to investigate the availability and equality in access to spacers.

384 CONCLUSION

Rectal toxicity is a considerable issue, and focus should be on minimising side effects of
 curative treatment. There is a strong and general agreement that all prostate cancer patients

undergoing radical RT have the potential to benefit from hydrogel spacers. Currently, not all
patients who could potentially benefit can access hydrogel spacers, and access is unequal.
Implementation of the ten strong and moderate consensus recommendations would likely help
prioritise and equalise access to rectal spacers for patients in the UK. In particular, prioritising
access towards patients on anticoagulation, with diabetes, and/or patients with inflammatory
bowel disease would, in our opinion, be a strong starting position.

to beet terien only

ACKNOWLEDGEMENTS

The authors would like to acknowledge Alice Craven and Dr. Glyn Burtt for supporting the manuscript development.

FUNDING STATEMENT

This study was supported by funding from Boston Scientific. Coreva Scientific GmbH & Co KG received consultancy fees from Boston Scientific for work related to this manuscript. SJ, AT, AE, AB, PD, CP, and HP were contracted for this study and reimbursed at fair, local market rates for their time commitment during the Delphi process but received no reimbursement for their participation in the manuscript development.

COMPETING INTERESTS

RS is the owner of Coreva Scientific, a health-economics and value-based healthcare consultancy that focuses on medical devices. AHH is an employee of Coreva Scientific. Coreva Scientific received consultancy fees from Boston Scientific for work related to this manuscript. The authors did not receive direct payment as a result of this work outside of their normal salary payments. EW is an employee of Boston Scientific.

AUTHOR CONTRIBUTIONS

EW conceptualised the idea. RS and AHH designed and ran the questionnaires and implemented data protection measures. EW reviewed the study design. AHH and RS analysed the responses. RS moderated the advisory boards. SJ, AT, AE, AB, PD, CP, and HP responded to the questionnaires, and participated in the advisory boards. AHH and RS drafted the manuscript, in collaboration with SJ, AT, AE, AB, PD, CP and HP. All authors critically reviewed the manuscript outline and manuscript drafts. All authors approved the final manuscript.

DATA SHARING STATEMENT

- No additional data available.

418 LEAD AUTHOR TRANSPARENCY STATEMENT

I confirm that the manuscript is an honest, accurate, and transparent account of the study
being reported; that no important aspects of the study have been omitted; and that any
discrepancies from the study as originally planned have been explained.

to beet teries only

422 Prof. Heather Ann Payne

Page 20 of 23

REFERENCES

- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660 [published Online First: 2021/02/05]
- 2. Cancer Research UK. Prostate cancer statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero accessed 2021-11-23.
- 3. Prostate cancer UK. Prostate information. About prostate cancer 2019 [Available from: https://prostatecanceruk.org/prostate-information/about-prostate-cancer accessed 2021-11-23.
- 4. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375(15):1415-24. doi: 10.1056/NEJMoa1606220 [published Online] First: 2016/09/15]
- 5. Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer 2020;129:41-49. doi: 10.1016/j.ejca.2020.01.011 [published Online First: 2020/03/03]
- 6. Nazim SM, Fawzy M, Bach C, et al. Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer. Arab J Urol 2018;16(4):367-77. doi: 10.1016/j.aju.2018.06.008 [published] Online First: 2018/12/121
- 7. Cancer Research UK. Prostate cancer treatment statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/diagnosis-and-treatment accessed 2021-10-26.
- 8. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management NICE guideline Published: 9 May 2019 2019.
- 9. Moris L, Cumberbatch MG, Van den Broeck T, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77(5):614-27. doi: 10.1016/j.eururo.2020.01.033 [published Online First: 2020/03/09]
- 10. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79(2):243-62. doi: 10.1016/j.eururo.2020.09.042 [published Online First: 2020/11/121
- 11. National Prostate Cancer Audit (NPCA). Annual Report 2020 Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019 (published January 2021)., 2021.
- Where 12. Prostate Matters. to access SBRT [Available from: https://prostatematters.co.uk/prostate-cancer/where-to-access-sbrt/ accessed 2021-11-26.

3	
4	-
5	
6	•
7	,
8	;
9)
1	0
1	1
1	2
1	3


> 13. Miller LE, Efstathiou JA, Bhattacharyya SK, et al. Association of the 468 Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of 469 Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review 470 Meta-analysis. JAMA Netw Open 2020;3(6):e208221. 471 and doi: 10.1001/jamanetworkopen.2020.8221 [published Online First: 472 2020/06/26] 473


474 14. Ardekani MA, Ghaffari H. Optimization of prostate brachytherapy
 475 techniques with polyethylene glycol–based hydrogel spacers: a
 476 systematic review. *Brachytherapy* 2020;19(1):13-23.


- 477 15. National Institute for Health and Care Excellence (NICE). 15 478 INTERVENTIONAL PROCEDURES PROGRAMME Equality impact 16 assessment IPG590 Biodegradable spacer insertion to reduce rectal 17 479 18 480 toxicity during radiotherapy for prostate cancer, 2016.
- 19 481 16. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective 20 482 Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical 21 22 483 Effects of Perirectal Spacer Application in Men Undergoing 23 484 Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 24 485 Radiat Oncol Biol Phys 2015;92(5):971-77. doi: 25 10.1016/j.ijrobp.2015.04.030 [published Online First: 20150423] 486 26
- 27 487 17. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal 28 Separation for Prostate Radiation Therapy: Final Results of a Phase III 488 29 489 Trial. Int J Radiat Oncol Biol Phys 2017;97(5):976-85. doi: 30 490 10.1016/j.ijrobp.2016.12.024 [published Online First: 2017/02/18] 31
- 3249118. Quinn TJ, Daignault-Newton S, Bosch W, et al. Who Benefits From a33492Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract34493Radiat Oncol 2020;10(3):186-94. doi: 10.1016/j.prro.2019.12.01136494[published Online First: 2020/01/25]
- 495
 495
 495
 496
 496
 497
 497
 19. Keeney S, Hasson F, McKenna H. Consulting the oracle: ten lessons from using the Delphi technique in nursing research. Journal of advanced nursing 2006;53(2):205-12.
 - 498 20. Keeney S, McKenna H, Hasson F. The Delphi technique in nursing and
 499 health research: John Wiley & Sons 2011.
- 43 21. Courtenay M, Deslandes R, Harries-Huntley G, et al. Classic e-Delphi 500 44 survey to provide national consensus and establish priorities with regards 501 45 to the factors that promote the implementation and continued 502 46 development of non-medical prescribing within health services in Wales. 503 47 48 BMJ Open 2018;8(9):e024161. doi: 10.1136/bmjopen-2018-024161 504 49 [published Online First: 2018/09/21] 505
- ⁵⁰ 506 22. Howarth E, Vainre M, Humphrey A, et al. Delphi study to identify key ⁵² 507 features of community-based child and adolescent mental health ⁵³ 508 services in the East of England. *BMJ Open* 2019;9(6):e022936. doi: ⁵⁴ 509 10.1136/bmjopen-2018-022936 [published Online First: 2019/06/22]
- 55 23. Snape D, Kirkham J, Preston J, et al. Exploring areas of consensus and 510 56 conflict around values underpinning public involvement in health and 511 57 58 Open 512 social care research: а modified Delphi study. BMJ 59
- 60

41

2014;4(1):e004217. doi: 10.1136/bmjopen-2013-004217 [published Online First: 2014/01/151 24. Taylor RM, Feltbower RG, Aslam N, et al. Modified international e-Delphi survey to define healthcare professional competencies for working with teenagers and young adults with cancer. BMJ Open 2016:6(5):e011361. doi: 10.1136/bmjopen-2016-011361 [published Online First: 2016/05/05] 25. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of studies. Clin Epidemiol 2014;67(4):401-9. Delphi J doi: 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04] 26. General Medical Council (GMC). Good medical practice 2019 [Available from: https://www.gmc-uk.org/-/media/documents/good-medical-practice---english-20200128 pdf-51527435.pdf. 27. Suneil Jain (Principal investigator). NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy (SABRE) 2021 [Available from: https://clinicaltrials.gov/ct2/show/NCT04905069?term=spaceoar&draw= 2&rank=1. Figure legends FIGURE 2: Strong consensus could only be reached if all experts indicated that they "Fully agree" or all except one "Fully agree", with the last respondent "Partially agree" with only a minor word change (score \geq 27). Moderate consensus could only be reached if at least five respondents "Fully agree", and with no "Disagree". Weak consensus was reached where a maximum of three respondents "Partially agree", and with no "Disagree". No consensus was indicated where at least one respondent "Disagree", or if four or more respondents "Partially agree". FIGURE 4: Key: BT, brachytherapy; LDR, low dose rate; HDR, high dose rate; PBT, proton beam therapy, IMRT, intensity-modulated radiation therapy; IGRT, image guided radiation therapy, SBRT, stereotactic body radiation therapy; SABR, stereotactic ablative radiotherapy Page 23 of 23







BMJ Open

1											
2 3											
4 5	BT monotherapy (LDR)								67		
6 7	BT monotherapy (HDR)								7	2	
8	PBT									75	
9 10	BT boost									76	
11 12	IMRT/IGRT: 74 Gy in 37 fx (2 Gy per fx)									78	
13	IMRT/IGRT: 60 Gy in 20 fx (3 Gy per fx)									79	
14 15	SBRT/SABR									80	
16 17		0	10	20	30	40	50	60	70	80	90
18											
19 20											
21 22											
23											
24 25											
26 27											
28 29											
30											
31 32											
33 34											
35											
36 37											
38 39											
40											
41 42											
43 44											
45											
46 47											
48 49											
50 51											
52											
53 54											
55 56											
57											
58 59											
60											

Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-060506.R1
Article Type:	Original research
Date Submitted by the Author:	05-Apr-2022
Complete List of Authors:	Payne, Heather; University College London Hospitals NHS Foundation Trust, Consultant Clinical Oncologist Jain, Suneil; Queen's University Belfast, School of Medicine, Dentistry and Biomedical Sciences Peedell, Clive; James Cook University Hospital, Department of Radiotherapy and Oncology Edwards, Albert; Kent Oncology Centre Thomas, James Andrew; Princess of Wales Hospital, Department of Urology Das, Prantik; University Hospitals of Derby and Burton NHS Foundation Trust, Department of Oncology Hansson Hedblom, Amanda; Coreva Scientific GmbH und Co KG Woodward, Emily; Boston Scientific AG Saunders, Rhodri; Coreva Scientific GmbH und Co KG Bahl, Amit; University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Radiology and imaging, Urology
Keywords:	Prostate disease < UROLOGY, Radiation oncology < RADIOLOGY & IMAGING, RADIOTHERAPY, Toxicity < THERAPEUTICS





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

1 Title page

Delphi study to identify consensus on patient selection for
hydrogel rectal spacer use during radiation therapy for prostate
cancer in the UK.

Short title: Delphi study on hydrogel rectal spacer use (UK)

Authors: Heather Ann Payne¹, Suneil Jain², Clive Peedell³, Albert Edwards⁴, James Andrew
 Thomas⁵, Prantik Das⁶, Amanda Hansson Hedblom⁷, Emily Woodward⁸, ^{IM} Rhodri Saunders⁷,

8 Amit Bahl⁹

Institutional affiliations: ¹Consultant Clinical Oncologist, University College London Hospitals NHS Foundation Trust, London, United Kingdom; ²School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom; 3Department of Radiotherapy and Oncology, James Cook University Hospital, Middlesbrough, United Kingdom; ⁴Kent Oncology Centre, Kent, United Kingdom; ⁵Department of Urology, Princess of Wales Hospital, Bridgend, United Kingdom; ⁶Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom; 7Coreva Scientific, Königswinter, Germany; ⁸Boston Scientific AG, Solothurn, Switzerland; ⁹Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, United Kingdom

Corresponding author:

19 Rhodri Saunders, Coreva Scientific GmbH & Co KG, Im Mühlenbruch 1, 53639 Königswinter,
20 North Rhine-Westphalia, Germany. rhodri@coreva-scientific.com

21 Word count: 3,971

BMJ Open

2 3 4	22	Delphi study to identify consensus on patient selection for
5 6 7	23	hydrogel rectal spacer use during radiation therapy for prostate
8 9 10 11	24	cancer in the UK.
12 13 14 15	25	Structured abstract (Word count: 268, max 300)
16 17	26	OBJECTIVES
18 19 20	27	To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation
21 22	28	therapy for the treatment of prostate cancer in the United Kingdom.
23 24 25	29	DESIGN
26 27	30	Delphi study consisting of two rounds of online questionnaires, two virtual advisory board
28 29	31	meetings and a final online questionnaire.
30 31 32 22	32	SETTING
33 34 35	33	Radical radiation therapy for localised and locally advanced prostate cancer in the United
36 37	34	Kingdom.
38 39 40	35	PARTICIPANTS
41 42	36	Six leading clinical oncologists and one urologist from across the UK.
43 44 45	37	INTERVENTIONS
46 47	38	Rectal hydrogel spacer.
48 49 50	39	PRIMARY AND SECONDARY OUTCOME MEASURES
51 52 53	40	NR
54 55	41	RESULTS
56 57 58	42	The panel reached consensus on the importance of minimizing toxicity for treatments with
59 60	43	curative intent, and that even low-grade toxicity-related adverse events can significantly
		Dage 2 of 25

Page 2 of 25

impact quality of life. There was agreement that despite meeting rectal dose constraints, too many patients experience rectal toxicity, and that rectal hydrogel spacers in eligible patients significantly reduces toxicity related adverse events. However, as a consequence of funding limitations, patients need to be prioritized for spacer use. A higher benefit of spacers can be expected in patients on anticoagulation, and in patients with diabetes or inflammatory bowel disease, but consensus could not be reached regarding patient groups expected to benefit less. While radiation therapy regimen is not a main factor determining prioritization, higher benefit is expected in ultra-hypofractionated regimens.

52 CONCLUSION

53 There is a strong and general agreement that all prostate cancer patients undergoing radical 54 radiation therapy have the potential to benefit from hydrogel spacers. Currently, not all patients 55 who could potentially benefit can access hydrogel spacers, and access is unequal. 56 Implementation of the consensus recommendations would likely help prioritise and equalise 57 access to rectal spacers for patients in the UK.

2 3 4	58	ARTICLE SUMMARY: STRENGTHS AND LIMITATIONS OF THIS STUDY
5 6	59	The Delphi panel is a recognised method in developing NICE guidelines and is utilised
7 8	60	here to gather insights from a diverse panel of UK radiation oncology and urology
9 10 11	61	experts who are experienced users of hydrogel spacers.
12	62	• This study included seven panel experts and their experiences may not reflect all users
14	63	of hydrogel spacers.
16 17	64	To help reduce bias, answers and opinions were assessed by two researchers working
12 13 14 15 16	65	independently.

INTRODUCTION

67 Prostate cancer burden

Prostate cancer is the second most common cancer in men globally,¹ and the most common in the UK.² More than 47,500 UK men are diagnosed with prostate cancer every year and over 400,000 men are living with and after prostate cancer.³ The 5-year survival rate for localized prostate cancer in the UK is almost 100%,⁴ with three guarters of men diagnosed at any stage expected to survive 10 years.² In England, 97%, 87% and 78% of men diagnosed with prostate cancer survive their disease for more than one, five and ten years, respectively.² Given the high likelihood of curative therapy, a key treatment goal is to prevent potential adverse events from impacting patient quality of life after treatment.

In addition to the patient burden, prostate cancer is a costly disease with the European costs
of care for prostate cancer estimated at EUR 199 billion in 2018.⁵

78 Radiation therapy for prostate cancer

Choice of treatment for prostate cancer is complex and involves multi-factorial considerations including presenting cancer stage (localised, locally advanced or metastatic), risk stratification, life expectancy, comorbidities, and other patient-specific factors, such as lifestyle, patient preference and treatment goals.⁶ For localised and locally advanced prostate cancer, treatment options include active surveillance, surgery, brachytherapy and radiation therapy (RT), with or without hormone treatment, as well as multimodality treatment combining surgery or RT with systemic therapy.⁷⁻⁹ RT with radical intent is a first-line treatment for localised and locally advanced prostate cancer.8 Intensity-modulated RT (IMRT) with image guidance (IGRT) is considered the gold-standard form of external beam RT (EBRT).¹⁰ Of the circa 18,000 men identified as having received radical RT for prostate cancer in England and Wales between April 2018 and March 2019, over 90% were treated with IMRT.¹¹ Whilst stereotactic body RT (SBRT) is not currently routine practice in the UK, its use is increasing and it is now

BMJ Open

91 delivered in several NHS centres.¹² Circa 95% of UK men with intermediate-risk disease
92 receive a hypofractionated radiotherapy regimen.¹¹

The success and clinical outcomes of RT depend on several factors, including radiation dose to the tumour and the extent of irradiation affecting nearby normal-tissue, particularly the rectum.¹⁰ Dose-escalated EBRT is a highly effective curative treatment, with higher doses providing better biochemical control.¹³ Higher doses can, however, increase radiation toxicity to nearby tissues. Despite substantial advancements in RT, acute and reversible, as well as rare but severe, long-term adverse effects of radiation toxicity such as urinary and bowel incontinence remain problematic. The National Prostate Cancer Audit (NPCA) reported that 11% of prostate cancer patients experienced ≥1 severe gastrointestinal complication within two years after radical RT. This outcome factor derived from hospital records data is defined as a confirmed diagnosis of radiation toxicity \geq grade 2 according to National Cancer Institute Common Toxicity Criteria for Adverse Events [CTCAE] in addition to a documented procedure to the large bowel.^{11 14} Late \geq grade 2 gastrointestinal toxicity has been explored in numerous randomized clinical trials. The 2016 Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO) trial found an incidence of gastrointestinal toxicity at three years of 17.7% in standard fractionation and 21.9% in hypofractionation.¹⁵ In 2017, results from the ASCENDE-RT trial showed a cumulative incidence of 5-year gastrointestinal side effects ranging from 20.2% (dose-escalated external beam radiation therapy) to 31.3% (low-dose-rate prostate brachytherapy).¹⁶ Due to its proximity to the prostate, the anterior rectal wall is especially vulnerable to irradiation effects and the rectum is a dose-limiting organ at risk.¹⁷

113 Hydrogel spacers

114 One way of reducing the unwanted radiation dose to the rectum is by increasing the space 115 between the prostate and the rectal wall. This can be achieved by use of a rectal spacer, with 116 three currently indicated for use during RT for prostate cancer in the UK: biodegradable

Page 6 of 25

> balloons, hyaluronic acid gel, and polyethylene glycol (PEG) hydrogel.¹⁸ In the UK, the use of biodegradable spacers to reduce rectal toxicity during RT for prostate cancer is accepted (IPG590) by NICE, based on safety and efficacy data on the use of PEG hydrogel spacers.¹⁸ Use of rectal hydrogel spacers has been evaluated in a single-blind, phase III trial in image guided IMRT (N=222).¹⁹ The spacer-placement success rate was 99%, and no device-related adverse events occurred.¹⁹ Late (three to 15 months) rectal toxicity severity was significantly reduced in the spacer group.¹⁹ At three years follow-up, decreased bowel toxicity and fewer declines in urinary and bowel quality of life were observed in the spacer group (41% men in the control group experienced a minimally important difference (MID) in decline in bowel quality of life vs 14% in the spacer group; P=0.002). The risk of large decline (twice the MID) was 21% (control) vs 5% (spacer; P=0.02) in bowel quality of life and 23% (control) vs 8% (spacer; P=0.02) in urinary guality of life respectively.²⁰

⁹129 Lack of routine reimbursement has led to restricted patient access to hydrogel spacers in the 130 UK. Therefore, there is a requirement to prioritise patients for hydrogel spacer use in the UK, 131 and attempts have been made to identify optimal usage. A secondary analysis of the hydrogel 132 spacer trial data tried to identify the patient subgroups most and least likely to benefit from the 133 intervention but found generally homogeneous results in bowel quality of life with benefits in 134 all assessed subgroups.²¹

135 The aim of this study was to identify consensus on patient prioritisation for rectal hydrogel 136 spacer use during RT for the treatment of prostate cancer in the UK.

- **METHODS**
- **The Delp**

The Delphi technique and panel experts

The Delphi technique is a structured, iterative, multistage process using rounds of questionnaires to collect opinions and to stepwise develop consensus among a pre-defined panel of experts.²² For this study, experts were approached and asked to participate in the panel based on being a UK radiation oncologist or urologist having experience with rectal

Page 7 of 25

Page 9 of 31

 BMJ Open

hydrogel spacers. To ensure a diverse panel, experts were sought to represent different
geographies within the UK and use different types of RT modalities. There is no defined
optimal panel size for a Delphi study,²³ but the selection of an odd number of experts ensured
that a majority outcome could be reached.

147 Steps in the Delphi process

There is no fixed number of rounds in a Delphi survey.²³ As depicted in Figure 1, our study adopted a five-stage approach to elicit consensus, consisting of two pre-advisory board questionnaires administered through a web-based survey program, two virtual advisory board discussions, and a final concluding questionnaire.

The first questionnaire provided some background information on the experts, such as their most used RT modalities and open-ended questions to capture a broad understanding. The open-ended questions related to key treatment aims, which patient and treatment characteristics to consider when prioritising hydrogel spacer, factors typically deterring them from recommending hydrogel spacer use, and factors predictive for toxicity. Additionally, experts were asked to rank treatment modalities in order of how much patient benefit they would expect from hydrogel spacer use, on a scale from 0 (no patient benefit) to 100 (maximal patient benefit).

In the second questionnaire, the responses to the open-ended questions from the previous
 questionnaire were presented, and the experts asked to rank them by order of importance. In
 addition to follow-up questions, the second questionnaire included questions on perceived
 barriers to hydrogel spacer use.

- 164 Figure 1: Overview of Delphi panel process
 - 165 Analysis and scoring

166 Qualitative content analysis was used to analyse responses to open-ended questions. Two167 researchers independently analysed responses and interpreted consensus. At the advisory

board meetings, results from the questionnaires were presented together with initial drafted consensus statements for discussion. Then followed moderated discussions which led to revisions of the consensus statements. In the final online questionnaire, the consensus statements were presented, and the experts asked to select a level of agreement: "I fully agree", "I partially agree" or "I disagree". Upon selecting "I partially agree", experts were asked to give a comment and/or update the wording of the statement. The responses were linked to an agreement score, based on the answer selected, and the comment given if "I partially agree" was selected (Table 1).

176 Table 1: Consensus statement scoring key

Score	Answer selected	Description
4	"I fully agree"	
3	"I partially agree"	With minor word change
2	"I partially agree"	With minor change to statement interpretation/meaning
1	"I disagree"	

Consensus definitions vary between studies²⁴⁻²⁸, with percent agreement being one of the more common approaches.²⁸ Based on the results of our final online survey, statements were categorised into four levels of consensus (strong, moderate, low, and no consensus). This study scored the level of consensus in terms of percent agreement, and additionally that consensus could not be reached in case any expert disagreed with a statement. Figure 2 depicts the consensus statement scoring for this study. Only statements grouped as either Strong or Moderate are considered statements where consensus was reached. Weak or No consensus mean that there was still substantial discussion or divergence of opinion among the experts.

48 100

 186 Figure 2: Consensus statement scoring, decision tree

51 187 **Consent, privacy, and data security**

The panel experts were informed about and consented to the full Delphi process, including
 <l

Page 9 of 25

3
4
5
6
7
8
9
10
11
10
12
13
14
15
16
17
18
19
20
21
22
∠∠ วว
20 21 22 23 24 25 26 27 28 29 30
24
25
26
27
28
29
30
31
32
33
34 35
35
36
37
38
39
40
41
42
43
44
44 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

206 207

60

stored for 60 days on the conference provider's EU based server. All experts were contracted
for this study and reimbursed at fair, local market rates for their time commitment during the
Delphi process. The study was approved by an independent review board (HML IRB Review
#952SCGC21).

196 Patient and public involvement

- 197 No patients involved.
- 198 **RESULTS**

199 Panel expert characteristics

All approached experts agreed to participate (N=7). Details on the panel experts' treatment practices are presented in Table 2. The majority of the panel (N=6) exclusively use rectal hydrogel spacers in their practices. One uses rectal hydrogel spacers as well as biodegradable balloons. Participation rates were high, with only one dropout (one expert did not complete the second questionnaire but participated in all other steps).

205 Table 2: Panel experts treatment practice

Geographical setting, N (%)	6				
England	5 (57)				
Northern Ireland	1 (14)				
Wales	1 (14)				
Public or private setting, N (%)					
Public only	1 (14)				
Private only	0 (0)				
Both	6 (86)				
Most frequently used RT modalities, % of patients (N experts using modality)					
IMRT	25–95 (6)				
EBRT (not specified)	90 (1)				
IMRT and HDR BT boost	15–30 (2)				
SBRT	45 (1)				
BT monotherapy (LDR)	10–20 (2)				
PBT	10 (1)				

Key: IMRT, intensity-modulated radiation therapy; EBRT, external beam radiation therapy; HDR, high dose rate; BT, brachytherapy; SBRT, stereotactic body radiation therapy; LDR, low dose rate; PBT, proton beam therapy.

Key treatment aims, besides curing or controlling cancer and increasing overall survival, wereto minimise the risk of side effects and toxicity.

210 Questionnaire outcomes shaping the consensus statement discussion

211 Questionnaire outcomes showed that the panel estimated considerably less toxicity in patients 212 with hydrogel spacer, as compared to those without (Figure 3). All experts agreed that 213 hydrogel spacers reduce grade 1 and 2 late rectal toxicity, 86% agreed that it reduces grade 214 3 toxicity and 71% grade 4 toxicity.

Figure 3: Expected level of late (after 3 months) rectal toxicity in patients with and without hydrogel spacer
 The panel considered toxicity a considerable issue, and underlined that also low-grade
 toxicity-related adverse events may significantly worsen patient's lives:

'I ask them [my patients], when you're out and about, is the first thing you think of where
the toilet is?... And a remarkable number of patients say yes to that question, and it is
affecting their quality of life.'

In the first questionnaire, the panel estimated that an average of 83% (SD: 13%) patients who
could potentially benefit from a hydrogel spacer were denied access. Throughout the
discussions, patient access in general and equal access in particular were central themes.
The panel voiced their concern, for example regarding differences between NHS and private
practice:

⁶/₇ 226 'In my private practice, every patient gets it [hydrogel spacer] unless there is a reason
 ⁸/₉ 227 why they should not get it. Whereas in my NHS practice, unfortunately no patient gets
 ⁰/₁ 228 it, unless there is a reason why they should get it.'

The main barrier to hydrogel spacer use was funding and resource constraints, followed bylack of trained staff.

Page 11 of 25

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

'The ideal way to go would be to offer it to every eligible patient. But given that this is not currently feasible in our centre, there has to be some kind of categorisation.'

As seen in Figure 4, a trend towards hypo-fractionated external-beam regimens, with potential increased bowel dose and toxicity being associated with more potential benefit for spacers was apparent. This was also reflected in the outcome of the conjoint analysis. The absolute variation between expected benefit was, however, relatively low, ranging from 67 (BT monotherapy LDR) to 80 (SBRT/SABR) on average. This was reflected in later discussions, where experts agreed that RT modality is not the main consideration when prioritising patients for hydrogel spacer use.

240 Figure 4: Expected patient benefit from hydrogel spacer use, by treatment modality

When asked about patient characteristics to consider when deciding whether to recommend using hydrogel spacer the experts gave a wide range of suggestions, including comorbidities (age, diabetes, high bleeding risk, hip prothesis, inflammatory bowel disease and rectal and bowel problems, normal erectile function), cancer stage, localisation, and heavy smoking. This was narrowed down in subsequent discussion, with general agreement that patients with certain comorbidities (diabetes, inflammatory bowel disease) or on anticoagulation may have higher benefit from hydrogel spacers.

248 Consensus statements

Upon being shown the results of the questionnaires, two rounds of moderated discussion followed, resulting in 13 consensus statements. These statements were subsequently voted on in a final questionnaire, and a final scoring was assigned as described in the method section.

253 The following eight statements reached strong consensus:

Our consensus opinion is that for treatments with curative intent, focus should be on
 minimising toxicity and the risk of side effects.

Page 12 of 25

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 14 of 31

BMJ Open

1

56

57

58

59

256	Our consensus opinion is that use of spacers in eligible patients significantly reduces
257	radiation dose to the rectum and toxicity-related adverse events.
258	• Our consensus opinion is that despite meeting rectal dose constraints, too many
259	patients continue to experience rectal toxicity.
260	• Our consensus opinion is that certain grade 1 toxicity-related adverse events ¹ can still
261	have a significant impact on patient quality of life.
262	• Our consensus opinion is that any toxicity grading system in use should be
263	complemented by patient-reported outcomes.
264	• Our consensus opinion is that patients receiving long-term anticoagulation therapy with
265	medications such as direct oral anticoagulants (DOACs) ² should be considered for
266	spacer use if their anticoagulation can be safely paused.
267	• Our consensus opinion is that spacers are useful in eligible patients with T1-T2
268	disease. Spacer use in patients with T2+ disease should not be excluded but should
269	be assessed on an individual basis by a team proficient in inserting spacers.
270	• Our consensus opinion is that patients should have the opportunity to take part in the
271	discussion regarding the use of a spacer. ²⁹
272	For the following two statements, moderate conserve was reached. Each statement is
	For the following two statements, moderate consensus was reached. Each statement is
273	followed by an explanation on why strong consensus was not reached.
274	• Our consensus opinion is that a higher benefit of spacers is expected in eligible
275	patients with certain comorbidities ³ and/or longer expected overall survival.
	¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal

¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal bleeding, rectal mucus.

² The reason for prescribing the DOAC, rather than the medication itself, is more important for the decision. All patients on DOACs, except for cardiac stent and prosthetic valve replacement patients may be able to safely pause their anticoagulation.

³ Anticoagulation, diabetes, inflammatory bowel disease (ulcerative colitis and Crohn's disease)

BMJ Open

Six experts (86%) fully agreed with the statement. One expert (14%) only partially agreed and
suggested removing "and/or longer expected overall survival". This was deemed a change to
the statement interpretation.

All eligible radiotherapy patients should have equal opportunity to access spacers,
 independent of socio-economic factors.

Five experts (71%) fully agreed with the statement. While there was an overall agreement that lack of equality in access to spacers is currently an important issue, two experts (29%) had rewording suggestions that would have impacted the statement interpretation. One proposed to add more detail on eligibility, and to add that patients suitable for a spacer implant should have access, irrespective of whether they can afford it. The other expert expressed some uncertainty regarding the term "socio-economic factors" and would have preferred the wording "irrespective of post-code".

1 288 Statements where no consensus was reached

289 One statement was categorised as a weak consensus statement:

Whilst we support the use of spacers in all eligible patients, our consensus opinion is
 that if resource constraints exist, patients receiving ultra-hypofractionated or
 hypofractionated radiotherapy should be prioritised for access to a spacer.

Four experts (57%) fully agreed with the statement. The remaining three (43%) partially agreed but had additional comments. One expert expressed that individual risk factors should be considered, rather than the RT modality. The second expert agreed on the need to identify a group at higher risk of rectal toxicity, and suggested combination of RT modality considerations and patient characteristics (e.g., age) and comorbidities. The third respondent only agreed that patients receiving ultra-hypofractionated RT should be prioritised.

299 For the following two statements, no consensus was reached.

Page 14 of 25

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Our consensus opinion is that for patients with anticipated short overall survival but
 who will receive radical radiotherapy, use of a spacer should only be considered after
 careful evaluation of potential benefit.

Three experts (43%) fully agreed. Four (57%) partially agreed but had additional comments. Two experts made the point that it is unlikely that patients with short anticipated overall survival would be indicated for radical radiotherapy. Two experts expressed uncertainty with the wording "overall survival". One of them suggested a rewording that some carefully selected patients with short expected survival who are offered radical radiotherapy may benefit from spacer use after careful consideration. The second expressed that the statement was too unclear. Additionally, in subsequent discussions, the experts agreed that the term "anticipated shorter life expectancy" would have been preferred over "anticipated short overall survival", so as not to imply that the use of hydrogel spacers affects survival. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement.

Our consensus opinion is that there are a limited number of patients with risk factors, or combination of risk factors, in which use of a spacer should only be considered after careful evaluation of potential benefits.

Four experts (57%) fully agreed, two (29%) partially agreed, and one (14%) disagreed. Those who partially agreed expressed that an addition should be made to the statement, that the majority of patients who receive radical RT would also be suitable for a spacer, noting that patients who are not fit enough for a spacer, likely are also not fit for RT. The second partially agreeing expert wanted to add a recommendation to discuss such cases with a mentor with extensive experience in spacer insertion. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement.

DISCUSSION

Statement of principal findings

There was strong consensus that rectal toxicity is a considerable issue, and that minimizing the risk of radiation side effects is an important treatment aim. Rectal hydrogel spacers can reduce the toxicity burden and benefit patients undergoing radical RT for the treatment of prostate cancer in the UK. Currently, the NHS does not routinely fund hydrogel spacers. Limited funding leads to limited resources, and therefore limited access. Experts estimated that on average, 83% of their patients that could benefit from a spacer are not currently getting access. There was moderate consensus that a higher benefit is expected in patients on anticoagulation, patients with diabetes, and patients with inflammatory bowel disease (Ulcerative colitis or Crohn's disease). However, experts expected the majority of patients to benefit from use of a spacer, and it was not possible to reach consensus on those patients with lower expected benefit. Key takeaways from discussions around statements where no consensus was reached are that individual patient characteristics are more important for informing the decision on whether to prioritise the use a spacer than the RT regimen selected. However, a higher level of benefit from spacer use is expected with ultra-hypofractionated RT compared with standard RT, a conclusion in line with current clinical evidence.³⁰

Meaning of the study: possible explanations and implications for clinicians and policy

makers

Currently, patient selection is driven by limitations in the healthcare system rather than patient needs. This highlights the importance of developing guidance on spacer use, to ensure fair and equal access to healthcare. The COVID-19 pandemic has lengthened already substantial NHS waiting times, further exacerbating issues with access and underscoring the need for formal guidance. Additionally, practical issues (e.g., availability of trained staff, theatre capacity) need to be considered when preparing a clinic to start using hydrogel spacers. As is

Page 16 of 25

important for all techniques to be introduced, audit of practice and quality improvement is recommended.

Strengths and weaknesses

This study only included seven experts, who are all experienced users of hydrogel spacers Naturally, a broader selection of experts could have resulted in different answers. However, including non-users as panel experts would not have been feasible for the purposes of this study, as they would have not possessed the relevant experience required. Additionally, the RT modality used by panel members could influence their view on when to prioritise hydrogel spacer use. However, the diversity of the panel in terms of modalities used likely safeguarded the balance of the resulting consensus.

The main strengths of this study are the scientific rigour applied following a well-defined and proven Delphi methodology, and the experience and diversity of the panel. The Delphi method allowed gathering insights from leading experts in the field from different UK countries utilising a mix of RT modalities, while reducing bias and separating the evaluation by tasking two independent researchers with analysis and scoring.

Comparison with other studies

To the best of our knowledge, no previous attempts have been done to establish consensus for rectal hydrogel spacer use in the UK. A study published in 2016 used a model-based approach to identify patients expected to benefit the most from implantable rectum spacers among 26 patients with localized prostate cancer treated at a German hospital. The clinical risk factors found relevant were anticoagulant use, hormonal therapy, antihypertensive use, diabetes, haemorrhoids, pelvic nodal RT, and prior abdominal surgery.³¹ Single-centre studies of rectal spacers in Crohn's and ulcerative colitis patients suggest benefit of spacers.^{32 33} One study conducted secondary analyses of a single-blinded, phase III randomised trial, with the aim of identifying patients benefitting the least from hydrogel rectal spacer during prostate

BMJ Open

375 radiation therapy.²¹ In line with this study, no subgroup without potential benefits of hydrogel
376 spacers could be identified. The benefit of hydrogel spacers perceived by the experts is in line
377 with current clinical evidence.²⁰

378 Unanswered questions and future research

This study offers guidance to later adopters of rectal hydrogel spacers, building on the expertise of leading UK radiation oncologists and urologist. Future research should focus on implementing formal guidance on hydrogel spacer use and strive towards reaching a consensus on patient prioritisation. A larger follow-up consensus study would be of value, asking all UK domain experts their opinion on the consensus statements. With growing interest in hydrogel spacers, it is increasingly important to study the impact of the quality of the implant. There is an ongoing debate on what a good implant is, and how it is measured. Similarly, it would be valuable to reach an agreement on which toxicity data to generate and follow up through including hydrogel spacers in cancer treatment trials, or through the development of a quality registry. Finally, it is of utmost importance to investigate the availability and equality in access to spacers. For this aim to be reached, further cost-effectiveness research and a continued discussion on willingness to pay should be undertaken. Analyses of spacers in prostate cancers have shown cost-effectiveness in certain radiation modalities in US^{34 35} and Dutch³⁶ contexts.

393 CONCLUSION

Rectal toxicity is a considerable issue, and focus should be on minimising side effects of curative treatment. There is a strong and general agreement that all prostate cancer patients undergoing radical RT have the potential to benefit from hydrogel spacers. Currently, not all patients who could potentially benefit can access hydrogel spacers, and access is unequal. Implementation of the ten strong and moderate consensus recommendations would likely help prioritise and equalise access to rectal spacers for patients in the UK. In particular, prioritising access towards patients on anticoagulation, with diabetes, and/or patients with inflammatory Jo bowel disease would, in our opinion, be a strong starting position.

1 2		
2 3 4	402	ACKNOWLEDGEMENTS
5 6	403	The authors would like to acknowledge Alice Craven and Dr. Glyn Burtt for supporting the
7 8 9	404	manuscript development.
9 10 11 12	405	FUNDING STATEMENT
13 14	406	This study was supported by funding from Boston Scientific. Coreva Scientific GmbH & Co KG
15 16	407	received consultancy fees from Boston Scientific for work related to this manuscript. SJ, AT,
17 18	408	AE, AB, PD, CP, and HP were contracted for this study and reimbursed at fair, local market
19 20	409	rates for their time commitment during the Delphi process but received no reimbursement for
21 22	410	their participation in the manuscript development.
23 24 25	411	
26 27	412	RS is the owner of Coreva Scientific, a health-economics and value-based healthcare
28 29 30 31 32 33 34	413	consultancy that focuses on medical devices. AHH is an employee of Coreva Scientific.
	414	Coreva Scientific received consultancy fees from Boston Scientific for work related to this
	415	manuscript. The authors did not receive direct payment as a result of this work outside of their
35 36	416	normal salary payments. EW is an employee of Boston Scientific.
37 38 39	417	AUTHOR CONTRIBUTIONS
40 41	418	EW conceptualised the idea. RS and AHH designed and ran the questionnaires and
42 43	419	implemented data protection measures. EW reviewed the study design. AHH and RS analysed
44 45	420	the responses. RS moderated the advisory boards. SJ, AT, AE, AB, PD, CP, and HP
46 47	421	responded to the questionnaires, and participated in the advisory boards. AHH and RS drafted
48 49 50	422	the manuscript, in collaboration with SJ, AT, AE, AB, PD, CP and HP. All authors critically
51 52	423	reviewed the manuscript outline and manuscript drafts. All authors approved the final
53 54 55	424	manuscript.
56 57		
58 59		

425 ETHICS APPROVAL STATEMENT

- 426 The study was approved by an independent review board (HML IRB Review #952SCGC21).
- 427 All participants gave informed consent before taking part.

11 428 DATA SHARING STATEMENT

429 No additional data available.

430 LEAD AUTHOR TRANSPARENCY STATEMENT

431 I confirm that the manuscript is an honest, accurate, and transparent account of the study
432 being reported; that no important aspects of the study have been omitted; and that any
433 discrepancies from the study as originally planned have been explained.

434 Prof. Heather Ann Payne



REFERENCES

- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660 [published Online First: 2021/02/05]
- 2. Cancer Research UK. Prostate cancer statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero accessed 2021-11-23.
- 3. Prostate cancer UK. Prostate information. About prostate cancer 2019 [Available from: https://prostatecanceruk.org/prostate-information/about-prostate-cancer accessed 2021-11-23.
- 4. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375(15):1415-24. doi: 10.1056/NEJMoa1606220 [published Online] First: 2016/09/15]
- 5. Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer 2020;129:41-49. doi: 10.1016/j.ejca.2020.01.011 [published Online First: 2020/03/03]
- 6. Nazim SM, Fawzy M, Bach C, et al. Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer. Arab J Urol 2018;16(4):367-77. doi: 10.1016/j.aju.2018.06.008 [published] Online First: 2018/12/121
- 7. Cancer Research UK. Prostate cancer treatment statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/diagnosis-and-treatment accessed 2021-10-26.
- 8. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management NICE guideline Published: 9 May 2019 2019.
- 9. Moris L, Cumberbatch MG, Van den Broeck T, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77(5):614-27. doi: 10.1016/j.eururo.2020.01.033 [published Online First: 2020/03/09]
- 10. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79(2):243-62. doi: 10.1016/j.eururo.2020.09.042 [published Online First: 2020/11/121
- 11. National Prostate Cancer Audit (NPCA). Annual Report 2020 Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019 (published January 2021)., 2021.
- Where 12. Prostate Matters. to access SBRT [Available from: https://prostatematters.co.uk/prostate-cancer/where-to-access-sbrt/ accessed 2021-11-26.

13. Miller LE, Efstathiou JA, Bhattacharyya SK, et al. Association of the

1 2 3

480

4 Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of 481 5 Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review 482 6 7 Meta-analysis. JAMA Netw Open 2020;3(6):e208221. 483 and doi: 8 10.1001/jamanetworkopen.2020.8221 [published Online First: 484 9 485 2020/06/26] 10 486 14. National Prostate Cancer Audit (NPCA). Annual Report 2020 Methodology 11 12 supplement, 2021. 487 13 15. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally 488 14 489 fractionated radiotherapy for patients with prostate cancer (HYPRO): late 15 490 toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet 16 2016;17(4):464-74. doi: 10.1016/s1470-2045(15)00567-7 17 491 Oncol 18 492 [published Online First: 20160309] 19 493 16. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An Analysis of 20 494 Treatment-Related Morbidity for a Randomized Trial Comparing a Low-21 22 495 Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam 23 Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat 496 24 Oncol Biol Phys 2017;98(2):286-95. doi: 10.1016/j.ijrobp.2017.01.008 497 25 498 [published Online First: 20170106] 26 27 499 17. Ardekani MA, Ghaffari H. Optimization of prostate brachytherapy 28 techniques with polyethylene glycol-based hydrogel spacers: a 500 29 501 systematic review. Brachytherapy 2020;19(1):13-23. 30 Health Care 502 18. National Institute for and Excellence (NICE). 31 INTERVENTIONAL PROCEDURES PROGRAMME Equality impact 32 503 33 504 assessment IPG590 Biodegradable spacer insertion to reduce rectal 34 toxicity during radiotherapy for prostate cancer, 2016. 505 35 19. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective 506 36 Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical 507 37 38 of Perirectal Spacer Application in 508 Effects Men Undergoing 39 Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 509 40 510 Radiat Oncol Biol Phys 2015;92(5):971-77. doi: 41 10.1016/j.jirobp.2015.04.030 [published Online First: 20150423] 511 42 43 20. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal 512 44 Separation for Prostate Radiation Therapy: Final Results of a Phase III 513 45 Radiat Oncol Biol Phys 2017;97(5):976-85. 514 Trial. Int J doi: 46 10.1016/j.ijrobp.2016.12.024 [published Online First: 2017/02/18] 515 47 48 21. Quinn TJ, Daignault-Newton S, Bosch W, et al. Who Benefits From a 516 49 Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract 517 50 Radiat Oncol 2020;10(3):186-94. doi: 10.1016/j.prro.2019.12.011 518 51 [published Online First: 2020/01/25] 52 519 53 22. Keeney S, Hasson F, McKenna H. Consulting the oracle: ten lessons from 520 54 using the Delphi technique in nursing research. Journal of advanced 521 55 nursing 2006;53(2):205-12. 522 56 23. Keeney S, McKenna H, Hasson F. The Delphi technique in nursing and 523 57 58 health research: John Wiley & Sons 2011. 524 59 60

24. Courtenay M, Deslandes R, Harries-Huntley G, et al. Classic e-Delphi

survey to provide national consensus and establish priorities with regards to the factors that promote the implementation and continued development of non-medical prescribing within health services in Wales. BMJ Open 2018;8(9):e024161. doi: 10.1136/bmjopen-2018-024161 [published Online First: 2018/09/21] 25. Howarth E, Vainre M, Humphrey A, et al. Delphi study to identify key features of community-based child and adolescent mental health services in the East of England. BMJ Open 2019;9(6):e022936. doi: 10.1136/bmjopen-2018-022936 [published Online First: 2019/06/22] 26. Snape D, Kirkham J, Preston J, et al. Exploring areas of consensus and conflict around values underpinning public involvement in health and social care research: а modified Delphi study. BMJ Open 2014;4(1):e004217. doi: 10.1136/bmjopen-2013-004217 [published Online First: 2014/01/15] 27. Taylor RM, Feltbower RG, Aslam N, et al. Modified international e-Delphi survey to define healthcare professional competencies for working with teenagers and young adults with cancer. BMJ Open 2016;6(5):e011361. doi: 10.1136/bmjopen-2016-011361 [published Online First: 2016/05/05] 28. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67(4):401-9. doi: 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04] 29. General Medical Council (GMC). Good medical practice 2019 [Available from: https://www.gmc-uk.org/-/media/documents/good-medical-practice---english-20200128 pdf-51527435.pdf. 30. Suneil Jain (Principal investigator). NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy (SABRE) 2021 [Available from: https://clinicaltrials.gov/ct2/show/NCT04905069?term=spaceoar&draw= 2&rank=1. 31. Vanneste BG, Hoffmann AL, van Lin EN, et al. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiother Oncol 2016;121(1):118-23. doi: 10.1016/j.radonc.2016.08.026 [published Online First: 20160916] 32. Vanneste BGL, Van Limbergen EJ, Marcelissen T, et al. Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? Clin Transl Radiat Oncol 2021;27:121-25. doi: 10.1016/j.ctro.2021.01.007 [published Online First: 20210125] 33. Vanneste BGL, Van Limbergen EJ, van de Beek K, et al. A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn's disease. Tech Innov Patient Support Radiat Oncol 2018;6:1-4. doi: 10.1016/j.tipsro.2018.01.004 [published Online First: 20180320] Page 24 of 25

- 34. Hutchinson RC, Sundaram V, Folkert M, et al. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. Urol 2016;34(7):291.e19-26. doi: 10.1016/j.urolonc.2016.02.024 Oncol [published Online First: 20160330]
- 57657635. Levy JF, Khairnar R, Louie AV, et al. Evaluating the Cost-Effectiveness of11577Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. Pract12578Radiat Oncol 2019;9(2):e172-e79. doi: 10.1016/j.prro.2018.10.00313579[published Online First: 20181017]
- 36. Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et al. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? Radiother Oncol 2015;114(2):276-81. doi: 10.1016/j.radonc.2015.01.005 [published Online First: 20150120]
- ²⁰ 584 Figure legends

²³ 24 585 **FIGURE 2**:


Strong consensus could only be reached if all experts indicated that they "Fully agree" or all except one "Fully agree", with the last respondent "Partially agree" with only a minor word change (score ≥27). Moderate consensus could only be reached if at least five respondents "Fully agree", and with no "Disagree". Weak consensus was reached where a maximum of three respondents "Partially agree", and with no "Disagree". No consensus was indicated where at least one respondent "Disagree", or if four or more respondents "Partially agree".


³⁹₄₀ 592 **FIGURE 4**:


593 Key: BT, brachytherapy; LDR, low dose rate; HDR, high dose rate; PBT, proton beam therapy,

594 IMRT, intensity-modulated radiation therapy; IGRT, image guided radiation therapy, SBRT,

595 stereotactic body radiation therapy; SABR, stereotactic ablative radiotherapy







1 2												
- 3 4	BT monotherapy (LDR)		1				I		67			
5 6	BT monotherapy (HDR)									72		
7	PBT								,	75		
8 9												
10	BT boost									76		
11 12	IMRT/IGRT: 74 Gy in 37 fx (2 Gy per fx)									78		
13 14	IMRT/IGRT: 60 Gy in 20 fx (3 Gy per fx)									79		
15	SBRT/SABR									80)	
16 17		0	10	20	30	40	50	60	70	80	90	100
18												
19 20												
21												
22 23												
24 25												
26												
27 28												
29												
30 31												
32 33												
34												
35 36												
37												
38 39												
40												
41 42												
43 44												
45												
46 47												
48												
49 50												
51												
52 53												
54												
55 56												
57												
58 59												
60												



Wolters Kluwer Thank You This PowerPoint document contains the images that you requested. ght Notice regials on this Site are protected by United States copyright law and may not be reproduction

Copyright Notice

All materials on this Site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Wolters Kluwer. You may not alter or remove any trademark, copyright or other notice. $\frac{4}{57}$

However, provided that you maintain all copyright, trademark and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only. Please refer to this link for further information on how to apply for permission for re-use

Any information posted to discussion forums (moderated and un-moderated) is for informational purposes only. We are not responsible for the information or the result of its practice.


For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



1	
2	
3	
4	
5	
6	
7	
8	
9	
1	0
1	1
' 1 1 1	2
1	3
1	4
	5
1	6
1	7
1	8
1	9
	0
2	1
2	2
2	
2	4
2	5
2	6 7 8
2	7
2	8
2	9
3	0
3	1
3	
3	3
3	
3	
- 3	6
_	_
3	7
3	6 7 8
3	9
3 4	7 8 9 0

Wolters Kluwer

	Title and abstract	
\$1	Title	Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g., athnography, grounded theory) or data collection methods (e.g., interview, focus group) is recommended
52	Abstract	Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results, and conclusions
	Introduction	
53	Problem formulation	Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement
\$4	Purpose or research question	Purpose of the study and specific objectives or questions
	Methods	
55	Qualitative approach and research paradigm	Qualitative approach (e.g., ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g., postpositivist, constructivist/ interpretrivist) is also recommended; rationale*
56	Researcher characteristics and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualification/lexperience, relationship with participants, assumptions, and/or presoppositions, potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results, and/or transferability
57	Contest	Setting/site and salient contextual factors; rationale ⁶
58	Sampling strategy	How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g., sampling saturation); rationale ⁶
59	Ethical issues pertaining to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues
510	Data collection methods	Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in response to evolving study findings; rationale ⁶
\$11	Data collection instruments and technologies	Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; it/how the instrument(s) changed over the course of the study
\$12	Units of study	Number and relevant characteristics of participants, documents, or events included in the study, level of participation (could be reported in results)
\$13	Data processing	Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/deidentification of excerpts
\$14	Data analysis	Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale *
\$15	Techniques to enhance trustworthiness	Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale ^b
	Results/findings	
516	Synthesis and interpretation	Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory.
\$17	Links to empirical data	Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings
	Discussion	
518	Integration with prior work, implications, transferability, and contribution(s) to the field	Short summary of main findings, explanation of how findings and conclusions connect to, support, ebiborate on, or challenge condusions of aedier scholaship; discussion of scope of application/ generalizability; identification of unique contribution(s) to scholarship in a discipline or field
\$19	Limitations	Trustworthiness and limitations of findings
	Other	
\$20	Conflicts of interest	Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed
521	Funding	Sources of funding and other support; role of funders in data collection, interpretation, and reporting
critical apprais contacting en research by p The nationale : rather than of	nated the SRQR by searching the literature to identify guidelines, re all criterie for qualitative research; eventries the reference liths of in perits to gain feedback. The SRQR list into to reprove the transparence, though being thousan the puritication for choosing that theory, appr their options available, the assumptions and limitations implicit in the nex study conclusions and shartheability. As appropriate, the relation	trieved sources; and of all aspects of qualitative pack, method, or technique sec choices, and how those



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Copyright © 2022 by the Association of American Medical Colleges

Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-060506.R2
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2022
Complete List of Authors:	Payne, Heather; University College London Hospitals NHS Foundation Trust, Consultant Clinical Oncologist Jain, Suneil; Queen's University Belfast, School of Medicine, Dentistry and Biomedical Sciences Peedell, Clive; James Cook University Hospital, Department of Radiotherapy and Oncology Edwards, Albert; Kent Oncology Centre Thomas, James Andrew; Princess of Wales Hospital, Department of Urology Das, Prantik; University Hospitals of Derby and Burton NHS Foundation Trust, Department of Oncology Hansson Hedblom, Amanda; Coreva Scientific GmbH und Co KG Woodward, Emily; Boston Scientific AG Saunders, Rhodri; Coreva Scientific GmbH und Co KG Bahl, Amit; University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Radiology and imaging, Urology
Keywords:	Prostate disease < UROLOGY, Radiation oncology < RADIOLOGY & IMAGING, RADIOTHERAPY, Toxicity < THERAPEUTICS





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

1 Title page

Delphi study to identify consensus on patient selection for
hydrogel rectal spacer use during radiation therapy for prostate
cancer in the UK.

Short title: Delphi study on hydrogel rectal spacer use (UK)

Authors: Heather Ann Payne¹, Suneil Jain², Clive Peedell³, Albert Edwards⁴, James Andrew
Thomas⁵, Prantik Das⁶, Amanda Hansson Hedblom⁷, Emily Woodward⁸, ^{IM} Rhodri Saunders⁷,

8 Amit Bahl⁹

Institutional affiliations: ¹Consultant Clinical Oncologist, University College London Hospitals NHS Foundation Trust, London, United Kingdom; ²School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom; 3Department of Radiotherapy and Oncology, James Cook University Hospital, Middlesbrough, United Kingdom; ⁴Kent Oncology Centre, Kent, United Kingdom; ⁵Department of Urology, Princess of Wales Hospital, Bridgend, United Kingdom; ⁶Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom; 7Coreva Scientific, Königswinter, Germany; ⁸Boston Scientific AG, Solothurn, Switzerland; ⁹Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, United Kingdom

Corresponding author:

19 Rhodri Saunders, Coreva Scientific GmbH & Co KG, Im Mühlenbruch 1, 53639 Königswinter,
20 North Rhine-Westphalia, Germany. rhodri@coreva-scientific.com

21 Word count: 3,971

BMJ Open

2 3 4	22	Delphi study to identify consensus on patient selection for
5 6 7 8	23	hydrogel rectal spacer use during radiation therapy for prostate
9 10 11	24	cancer in the UK.
12 13 14 15	25	Structured abstract (Word count: 268, max 300)
16 17	26	OBJECTIVES
18 19 20	27	To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation
21 22	28	therapy for the treatment of prostate cancer in the United Kingdom.
23 24 25	29	DESIGN
26 27	30	Delphi study consisting of two rounds of online questionnaires, two virtual advisory board
28 29	31	meetings and a final online questionnaire.
30 31 32 22	32	SETTING
33 34 35	33	Radical radiation therapy for localised and locally advanced prostate cancer in the United
36 37	34	Kingdom.
38 39 40	35	PARTICIPANTS
41 42	36	Six leading clinical oncologists and one urologist from across the UK.
43 44 45	37	INTERVENTIONS
46 47	38	Rectal hydrogel spacer.
48 49 50	39	PRIMARY AND SECONDARY OUTCOME MEASURES
51 52 53	40	NR
54 55	41	RESULTS
56 57 58	42	The panel reached consensus on the importance of minimizing toxicity for treatments with
59 60	43	curative intent, and that even low-grade toxicity-related adverse events can significantly
		Dage 2 of 25

Page 2 of 25

impact quality of life. There was agreement that despite meeting rectal dose constraints, too many patients experience rectal toxicity, and that rectal hydrogel spacers in eligible patients significantly reduces toxicity related adverse events. However, as a consequence of funding limitations, patients need to be prioritized for spacer use. A higher benefit of spacers can be expected in patients on anticoagulation, and in patients with diabetes or inflammatory bowel disease, but consensus could not be reached regarding patient groups expected to benefit less. While radiation therapy regimen is not a main factor determining prioritization, higher benefit is expected in ultra-hypofractionated regimens.

52 CONCLUSION

53 There is a strong and general agreement that all prostate cancer patients undergoing radical 54 radiation therapy have the potential to benefit from hydrogel spacers. Currently, not all patients 55 who could potentially benefit can access hydrogel spacers, and access is unequal. 56 Implementation of the consensus recommendations would likely help prioritise and equalise 57 access to rectal spacers for patients in the UK.

2 3 4	58	ARTICLE SUMMARY: STRENGTHS AND LIMITATIONS OF THIS STUDY
5 6	59	The Delphi panel is a recognised method in developing NICE guidelines and is utilised
7 8	60	here to gather insights from a diverse panel of UK radiation oncology and urology
9 10 11	61	experts who are experienced users of hydrogel spacers.
12 13	62	• This study included seven panel experts and their experiences may not reflect all users
14 15	63	of hydrogel spacers.
16 17	64	To help reduce bias, answers and opinions were assessed by two researchers working
18 19 20 21 22 23 24 25 26 27 28 29 30 31 23 34 35 36 37 38 9 40 41 42 43 44 50 51 52 53 54 55 56 7 8 9 60	65	independently.

INTRODUCTION

67 Prostate cancer burden

Prostate cancer is the second most common cancer in men globally,¹ and the most common in the UK.² More than 47,500 UK men are diagnosed with prostate cancer every year and over 400,000 men are living with and after prostate cancer.³ The 5-year survival rate for localized prostate cancer in the UK is almost 100%,⁴ with three guarters of men diagnosed at any stage expected to survive 10 years.² In England, 97%, 87% and 78% of men diagnosed with prostate cancer survive their disease for more than one, five and ten years, respectively.² Given the high likelihood of curative therapy, a key treatment goal is to prevent potential adverse events from impacting patient quality of life after treatment.

In addition to the patient burden, prostate cancer is a costly disease with the European costs
of care for prostate cancer estimated at EUR 199 billion in 2018.⁵

78 Radiation therapy for prostate cancer

Choice of treatment for prostate cancer is complex and involves multi-factorial considerations including presenting cancer stage (localised, locally advanced or metastatic), risk stratification, life expectancy, comorbidities, and other patient-specific factors, such as lifestyle, patient preference and treatment goals.⁶ For localised and locally advanced prostate cancer, treatment options include active surveillance, surgery, brachytherapy and radiation therapy (RT), with or without hormone treatment, as well as multimodality treatment combining surgery or RT with systemic therapy.⁷⁻⁹ RT with radical intent is a first-line treatment for localised and locally advanced prostate cancer.8 Intensity-modulated RT (IMRT) with image guidance (IGRT) is considered the gold-standard form of external beam RT (EBRT).¹⁰ Of the circa 18,000 men identified as having received radical RT for prostate cancer in England and Wales between April 2018 and March 2019, over 90% were treated with IMRT.¹¹ Whilst stereotactic body RT (SBRT) is not currently routine practice in the UK, its use is increasing and it is now

BMJ Open

91 delivered in several NHS centres.¹² Circa 95% of UK men with intermediate-risk disease
92 receive a hypofractionated radiotherapy regimen.¹¹

The success and clinical outcomes of RT depend on several factors, including radiation dose to the tumour and the extent of irradiation affecting nearby normal-tissue, particularly the rectum.¹⁰ Dose-escalated EBRT is a highly effective curative treatment, with higher doses providing better biochemical control.¹³ Higher doses can, however, increase radiation toxicity to nearby tissues. Despite substantial advancements in RT, acute and reversible, as well as rare but severe, long-term adverse effects of radiation toxicity such as urinary and bowel incontinence remain problematic. The National Prostate Cancer Audit (NPCA) reported that 11% of prostate cancer patients experienced ≥1 severe gastrointestinal complication within two years after radical RT. This outcome factor derived from hospital records data is defined as a confirmed diagnosis of radiation toxicity \geq grade 2 according to National Cancer Institute Common Toxicity Criteria for Adverse Events [CTCAE] in addition to a documented procedure to the large bowel.^{11 14} Late \geq grade 2 gastrointestinal toxicity has been explored in numerous randomized clinical trials. The 2016 Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO) trial found an incidence of gastrointestinal toxicity at three years of 17.7% in standard fractionation and 21.9% in hypofractionation.¹⁵ In 2017, results from the ASCENDE-RT trial showed a cumulative incidence of 5-year gastrointestinal side effects ranging from 20.2% (dose-escalated external beam radiation therapy) to 31.3% (low-dose-rate prostate brachytherapy).¹⁶ Due to its proximity to the prostate, the anterior rectal wall is especially vulnerable to irradiation effects and the rectum is a dose-limiting organ at risk.¹⁷

113 Hydrogel spacers

114 One way of reducing the unwanted radiation dose to the rectum is by increasing the space 115 between the prostate and the rectal wall. This can be achieved by use of a rectal spacer, with 116 three currently indicated for use during RT for prostate cancer in the UK: biodegradable

Page 6 of 25

> balloons, hyaluronic acid gel, and polyethylene glycol (PEG) hydrogel.¹⁸ In the UK, the use of biodegradable spacers to reduce rectal toxicity during RT for prostate cancer is accepted (IPG590) by NICE, based on safety and efficacy data on the use of PEG hydrogel spacers.¹⁸ Use of rectal hydrogel spacers has been evaluated in a single-blind, phase III trial in image guided IMRT (N=222).¹⁹ The spacer-placement success rate was 99%, and no device-related adverse events occurred.¹⁹ Late (three to 15 months) rectal toxicity severity was significantly reduced in the spacer group.¹⁹ At three years follow-up, decreased bowel toxicity and fewer declines in urinary and bowel quality of life were observed in the spacer group (41% men in the control group experienced a minimally important difference (MID) in decline in bowel quality of life vs 14% in the spacer group; P=0.002). The risk of large decline (twice the MID) was 21% (control) vs 5% (spacer; P=0.02) in bowel quality of life and 23% (control) vs 8% (spacer; P=0.02) in urinary guality of life respectively.²⁰

⁹129 Lack of routine reimbursement has led to restricted patient access to hydrogel spacers in the 130 UK. Therefore, there is a requirement to prioritise patients for hydrogel spacer use in the UK, 131 and attempts have been made to identify optimal usage. A secondary analysis of the hydrogel 132 spacer trial data tried to identify the patient subgroups most and least likely to benefit from the 133 intervention but found generally homogeneous results in bowel quality of life with benefits in 134 all assessed subgroups.²¹

135 The aim of this study was to identify consensus on patient prioritisation for rectal hydrogel 136 spacer use during RT for the treatment of prostate cancer in the UK.

- **METHODS**
- **The Delp**

The Delphi technique and panel experts

The Delphi technique is a structured, iterative, multistage process using rounds of questionnaires to collect opinions and to stepwise develop consensus among a pre-defined panel of experts.²² For this study, experts were approached and asked to participate in the panel based on being a UK radiation oncologist or urologist having experience with rectal

Page 7 of 25

Page 9 of 31

 BMJ Open

hydrogel spacers. To ensure a diverse panel, experts were sought to represent different
geographies within the UK and use different types of RT modalities. There is no defined
optimal panel size for a Delphi study,²³ but the selection of an odd number of experts ensured
that a majority outcome could be reached.

147 Steps in the Delphi process

There is no fixed number of rounds in a Delphi survey.²³ As depicted in Figure 1, our study adopted a five-stage approach to elicit consensus, consisting of two pre-advisory board questionnaires administered through a web-based survey program, two virtual advisory board discussions, and a final concluding questionnaire.

The first questionnaire provided some background information on the experts, such as their most used RT modalities and open-ended questions to capture a broad understanding. The open-ended questions related to key treatment aims, which patient and treatment characteristics to consider when prioritising hydrogel spacer, factors typically deterring them from recommending hydrogel spacer use, and factors predictive for toxicity. Additionally, experts were asked to rank treatment modalities in order of how much patient benefit they would expect from hydrogel spacer use, on a scale from 0 (no patient benefit) to 100 (maximal patient benefit).

In the second questionnaire, the responses to the open-ended questions from the previous
 questionnaire were presented, and the experts asked to rank them by order of importance. In
 addition to follow-up questions, the second questionnaire included questions on perceived
 barriers to hydrogel spacer use.

- 164 Figure 1: Overview of Delphi panel process
 - 165 Analysis and scoring

166 Qualitative content analysis was used to analyse responses to open-ended questions. Two167 researchers independently analysed responses and interpreted consensus. At the advisory

board meetings, results from the questionnaires were presented together with initial drafted consensus statements for discussion. Then followed moderated discussions which led to revisions of the consensus statements. In the final online questionnaire, the consensus statements were presented, and the experts asked to select a level of agreement: "I fully agree", "I partially agree" or "I disagree". Upon selecting "I partially agree", experts were asked to give a comment and/or update the wording of the statement. The responses were linked to an agreement score, based on the answer selected, and the comment given if "I partially agree" was selected (Table 1).

176 Table 1: Consensus statement scoring key

Score	Answer selected	Description
4	"I fully agree"	
3	"I partially agree"	With minor word change
2	"I partially agree"	With minor change to statement interpretation/meaning
1	"I disagree"	

Consensus definitions vary between studies²⁴⁻²⁸, with percent agreement being one of the more common approaches.²⁸ Based on the results of our final online survey, statements were categorised into four levels of consensus (strong, moderate, low, and no consensus). This study scored the level of consensus in terms of percent agreement, and additionally that consensus could not be reached in case any expert disagreed with a statement. Figure 2 depicts the consensus statement scoring for this study. Only statements grouped as either Strong or Moderate are considered statements where consensus was reached. Weak or No consensus mean that there was still substantial discussion or divergence of opinion among the experts.

48 100

 186 Figure 2: Consensus statement scoring, decision tree

51 187 **Consent, privacy, and data security**

The panel experts were informed about and consented to the full Delphi process, including
 <l

Page 9 of 25

3
4
5
6
7
8
9
10
11
10
12
13
14
15
16
17
18
19
20
21
22
∠∠ วว
20 21 22 23 24 25 26 27 28 29 30
24
25
26
27
28
29
30
31
32
33
34 35
35
36
37
38
39
40
41
42
43
44
44 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

206 207

60

stored for 60 days on the conference provider's EU based server. All experts were contracted
for this study and reimbursed at fair, local market rates for their time commitment during the
Delphi process. The study was approved by an independent review board (HML IRB Review
#952SCGC21).

196 Patient and public involvement

- 197 No patients involved.
- 198 **RESULTS**

199 Panel expert characteristics

All approached experts agreed to participate (N=7). Details on the panel experts' treatment practices are presented in Table 2. The majority of the panel (N=6) exclusively use rectal hydrogel spacers in their practices. One uses rectal hydrogel spacers as well as biodegradable balloons. Participation rates were high, with only one dropout (one expert did not complete the second questionnaire but participated in all other steps).

205 Table 2: Panel experts treatment practice

Geographical setting, N (%)	6
England	5 (57)
Northern Ireland	1 (14)
Wales	1 (14)
Public or private setting, N (%)	
Public only	1 (14)
Private only	0 (0)
Both	6 (86)
Most frequently used RT modalities, % of patients	(N experts using modality)
IMRT	25–95 (6)
EBRT (not specified)	90 (1)
IMRT and HDR BT boost	15–30 (2)
SBRT	45 (1)
BT monotherapy (LDR)	10–20 (2)
PBT	10 (1)

Key: IMRT, intensity-modulated radiation therapy; EBRT, external beam radiation therapy; HDR, high dose rate; BT, brachytherapy; SBRT, stereotactic body radiation therapy; LDR, low dose rate; PBT, proton beam therapy.

Key treatment aims, besides curing or controlling cancer and increasing overall survival, wereto minimise the risk of side effects and toxicity.

210 Questionnaire outcomes shaping the consensus statement discussion

211 Questionnaire outcomes showed that the panel estimated considerably less toxicity in patients 212 with hydrogel spacer, as compared to those without (Figure 3). All experts agreed that 213 hydrogel spacers reduce grade 1 and 2 late rectal toxicity, 86% agreed that it reduces grade 214 3 toxicity and 71% grade 4 toxicity.

Figure 3: Expected level of late (after 3 months) rectal toxicity in patients with and without hydrogel spacer
 The panel considered toxicity a considerable issue, and underlined that also low-grade
 toxicity-related adverse events may significantly worsen patient's lives:

'I ask them [my patients], when you're out and about, is the first thing you think of where
the toilet is?... And a remarkable number of patients say yes to that question, and it is
affecting their quality of life.'

In the first questionnaire, the panel estimated that an average of 83% (SD: 13%) patients who
could potentially benefit from a hydrogel spacer were denied access. Throughout the
discussions, patient access in general and equal access in particular were central themes.
The panel voiced their concern, for example regarding differences between NHS and private
practice:

⁶/₇ 226 'In my private practice, every patient gets it [hydrogel spacer] unless there is a reason
 ⁸/₉ 227 why they should not get it. Whereas in my NHS practice, unfortunately no patient gets
 ⁰/₁ 228 it, unless there is a reason why they should get it.'

The main barrier to hydrogel spacer use was funding and resource constraints, followed bylack of trained staff.

Page 11 of 25

BMJ Open

'The ideal way to go would be to offer it to every eligible patient. But given that this is not currently feasible in our centre, there has to be some kind of categorisation.'

As seen in Figure 4, a trend towards hypo-fractionated external-beam regimens, with potential increased bowel dose and toxicity being associated with more potential benefit for spacers was apparent. This was also reflected in the outcome of the conjoint analysis. The absolute variation between expected benefit was, however, relatively low, ranging from 67 (BT monotherapy LDR) to 80 (SBRT/SABR) on average. This was reflected in later discussions, where experts agreed that RT modality is not the main consideration when prioritising patients for hydrogel spacer use.

240 Figure 4: Expected patient benefit from hydrogel spacer use, by treatment modality

When asked about patient characteristics to consider when deciding whether to recommend using hydrogel spacer the experts gave a wide range of suggestions, including comorbidities (age, diabetes, high bleeding risk, hip prothesis, inflammatory bowel disease and rectal and bowel problems, normal erectile function), cancer stage, localisation, and heavy smoking. This was narrowed down in subsequent discussion, with general agreement that patients with certain comorbidities (diabetes, inflammatory bowel disease) or on anticoagulation may have higher benefit from hydrogel spacers.

248 Consensus statements

Upon being shown the results of the questionnaires, two rounds of moderated discussion followed, resulting in 13 consensus statements. These statements were subsequently voted on in a final questionnaire, and a final scoring was assigned as described in the method section.

253 The following eight statements reached strong consensus:

Our consensus opinion is that for treatments with curative intent, focus should be on
 minimising toxicity and the risk of side effects.

Page 12 of 25

Page 14 of 31

BMJ Open

1

56

57

58

59

256	Our consensus opinion is that use of spacers in eligible patients significantly reduces
257	radiation dose to the rectum and toxicity-related adverse events.
258	• Our consensus opinion is that despite meeting rectal dose constraints, too many
259	patients continue to experience rectal toxicity.
260	• Our consensus opinion is that certain grade 1 toxicity-related adverse events ¹ can still
261	have a significant impact on patient quality of life.
262	• Our consensus opinion is that any toxicity grading system in use should be
263	complemented by patient-reported outcomes.
264	• Our consensus opinion is that patients receiving long-term anticoagulation therapy with
265	medications such as direct oral anticoagulants (DOACs) ² should be considered for
266	spacer use if their anticoagulation can be safely paused.
267	• Our consensus opinion is that spacers are useful in eligible patients with T1-T2
268	disease. Spacer use in patients with T2+ disease should not be excluded but should
269	be assessed on an individual basis by a team proficient in inserting spacers.
270	• Our consensus opinion is that patients should have the opportunity to take part in the
271	discussion regarding the use of a spacer. ²⁹
272	For the following two statements, moderate conserve was reached. Each statement is
	For the following two statements, moderate consensus was reached. Each statement is
273	followed by an explanation on why strong consensus was not reached.
274	• Our consensus opinion is that a higher benefit of spacers is expected in eligible
275	patients with certain comorbidities ³ and/or longer expected overall survival.
	¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal

¹ Bowel frequency and urgency, diarrhoea, flatulence, radiation cystitis, radiation proctitis, rectal bleeding, rectal mucus.

² The reason for prescribing the DOAC, rather than the medication itself, is more important for the decision. All patients on DOACs, except for cardiac stent and prosthetic valve replacement patients may be able to safely pause their anticoagulation.

³ Anticoagulation, diabetes, inflammatory bowel disease (ulcerative colitis and Crohn's disease)

BMJ Open

Six experts (86%) fully agreed with the statement. One expert (14%) only partially agreed and
suggested removing "and/or longer expected overall survival". This was deemed a change to
the statement interpretation.

All eligible radiotherapy patients should have equal opportunity to access spacers,
 independent of socio-economic factors.

Five experts (71%) fully agreed with the statement. While there was an overall agreement that lack of equality in access to spacers is currently an important issue, two experts (29%) had rewording suggestions that would have impacted the statement interpretation. One proposed to add more detail on eligibility, and to add that patients suitable for a spacer implant should have access, irrespective of whether they can afford it. The other expert expressed some uncertainty regarding the term "socio-economic factors" and would have preferred the wording "irrespective of post-code".

1 288 Statements where no consensus was reached

289 One statement was categorised as a weak consensus statement:

Whilst we support the use of spacers in all eligible patients, our consensus opinion is
 that if resource constraints exist, patients receiving ultra-hypofractionated or
 hypofractionated radiotherapy should be prioritised for access to a spacer.

Four experts (57%) fully agreed with the statement. The remaining three (43%) partially agreed but had additional comments. One expert expressed that individual risk factors should be considered, rather than the RT modality. The second expert agreed on the need to identify a group at higher risk of rectal toxicity, and suggested combination of RT modality considerations and patient characteristics (e.g., age) and comorbidities. The third respondent only agreed that patients receiving ultra-hypofractionated RT should be prioritised.

299 For the following two statements, no consensus was reached.

Page 14 of 25

Our consensus opinion is that for patients with anticipated short overall survival but
 who will receive radical radiotherapy, use of a spacer should only be considered after
 careful evaluation of potential benefit.

Three experts (43%) fully agreed. Four (57%) partially agreed but had additional comments. Two experts made the point that it is unlikely that patients with short anticipated overall survival would be indicated for radical radiotherapy. Two experts expressed uncertainty with the wording "overall survival". One of them suggested a rewording that some carefully selected patients with short expected survival who are offered radical radiotherapy may benefit from spacer use after careful consideration. The second expressed that the statement was too unclear. Additionally, in subsequent discussions, the experts agreed that the term "anticipated shorter life expectancy" would have been preferred over "anticipated short overall survival", so as not to imply that the use of hydrogel spacers affects survival. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement.

Our consensus opinion is that there are a limited number of patients with risk factors, or combination of risk factors, in which use of a spacer should only be considered after careful evaluation of potential benefits.

Four experts (57%) fully agreed, two (29%) partially agreed, and one (14%) disagreed. Those who partially agreed expressed that an addition should be made to the statement, that the majority of patients who receive radical RT would also be suitable for a spacer, noting that patients who are not fit enough for a spacer, likely are also not fit for RT. The second partially agreeing expert wanted to add a recommendation to discuss such cases with a mentor with extensive experience in spacer insertion. Upon subsequent discussion, experts agreed that the statement would have been improved by adding "and side effects" to the end of the statement.

DISCUSSION

Statement of principal findings

There was strong consensus that rectal toxicity is a considerable issue, and that minimizing the risk of radiation side effects is an important treatment aim. Rectal hydrogel spacers can reduce the toxicity burden and benefit patients undergoing radical RT for the treatment of prostate cancer in the UK. Currently, the NHS does not routinely fund hydrogel spacers. Limited funding leads to limited resources, and therefore limited access. Experts estimated that on average, 83% of their patients that could benefit from a spacer are not currently getting access. There was moderate consensus that a higher benefit is expected in patients on anticoagulation, patients with diabetes, and patients with inflammatory bowel disease (Ulcerative colitis or Crohn's disease). However, experts expected the majority of patients to benefit from use of a spacer, and it was not possible to reach consensus on those patients with lower expected benefit. Key takeaways from discussions around statements where no consensus was reached are that individual patient characteristics are more important for informing the decision on whether to prioritise the use a spacer than the RT regimen selected. However, a higher level of benefit from spacer use is expected with ultra-hypofractionated RT compared with standard RT, a conclusion in line with current clinical evidence.³⁰

Meaning of the study: possible explanations and implications for clinicians and policy

makers

Currently, patient selection is driven by limitations in the healthcare system rather than patient needs. This highlights the importance of developing guidance on spacer use, to ensure fair and equal access to healthcare. The COVID-19 pandemic has lengthened already substantial NHS waiting times, further exacerbating issues with access and underscoring the need for formal guidance. Additionally, practical issues (e.g., availability of trained staff, theatre capacity) need to be considered when preparing a clinic to start using hydrogel spacers. As is

Page 16 of 25

important for all techniques to be introduced, audit of practice and quality improvement is recommended.

Strengths and weaknesses

This study only included seven experts, who are all experienced users of hydrogel spacers Naturally, a broader selection of experts could have resulted in different answers. However, including non-users as panel experts would not have been feasible for the purposes of this study, as they would have not possessed the relevant experience required. Additionally, the RT modality used by panel members could influence their view on when to prioritise hydrogel spacer use. However, the diversity of the panel in terms of modalities used likely safeguarded the balance of the resulting consensus.

The main strengths of this study are the scientific rigour applied following a well-defined and proven Delphi methodology, and the experience and diversity of the panel. The Delphi method allowed gathering insights from leading experts in the field from different UK countries utilising a mix of RT modalities, while reducing bias and separating the evaluation by tasking two independent researchers with analysis and scoring.

Comparison with other studies

To the best of our knowledge, no previous attempts have been done to establish consensus for rectal hydrogel spacer use in the UK. A study published in 2016 used a model-based approach to identify patients expected to benefit the most from implantable rectum spacers among 26 patients with localized prostate cancer treated at a German hospital. The clinical risk factors found relevant were anticoagulant use, hormonal therapy, antihypertensive use, diabetes, haemorrhoids, pelvic nodal RT, and prior abdominal surgery.³¹ Single-centre studies of rectal spacers in Crohn's and ulcerative colitis patients suggest benefit of spacers.^{32 33} One study conducted secondary analyses of a single-blinded, phase III randomised trial, with the aim of identifying patients benefitting the least from hydrogel rectal spacer during prostate

BMJ Open

radiation therapy.²¹ In line with this study, no subgroup without potential benefits of hydrogel spacers could be identified. The benefit of hydrogel spacers perceived by the experts is in line with current clinical evidence.20 Unanswered questions and future research

As well as hydrogel rectal spacers, other materials including hyaluronic acid, saline-filled balloon, and human collagen have been used to create space between the rectum and prostate. Readers should familiarize themselves with the available evidence on each product when considering between the different options. This study offers guidance to later adopters of rectal hydrogel spacers, building on the expertise of leading UK radiation oncologists and urologist. Future research should focus on implementing formal guidance on hydrogel spacer use and strive towards reaching a consensus on patient prioritisation. A larger follow-up consensus study would be of value, asking all UK domain experts their opinion on the consensus statements. With growing interest in hydrogel spacers, it is increasingly important to study the impact of the quality of the implant. There is an ongoing debate on what a good implant is, and how it is measured. Similarly, it would be valuable to reach an agreement on which toxicity data to generate and follow up through including hydrogel spacers in cancer treatment trials, or through the development of a quality registry. Finally, it is of utmost importance to investigate the availability and equality in access to spacers. For this aim to be reached, further cost-effectiveness research and a continued discussion on willingness to pay should be undertaken. Analyses of spacers in prostate cancers have shown cost-effectiveness in certain radiation modalities in US^{34 35} and Dutch³⁶ contexts.

CONCLUSION

Rectal toxicity is a considerable issue, and focus should be on minimising side effects of curative treatment. There is a strong and general agreement that all prostate cancer patients undergoing radical RT have the potential to benefit from hydrogel spacers. Currently, not all patients who could potentially benefit can access hydrogel spacers, and access is unequal.

Implementation of the ten strong and moderate consensus recommendations would likely help prioritise and equalise access to rectal spacers for patients in the UK. In particular, prioritising access towards patients on anticoagulation, with diabetes, and/or patients with inflammatory bowel disease would, in our opinion, be a strong starting position.

s, igulation pinion, be a stro.

1 2		
2 3 4	405	ACKNOWLEDGEMENTS
5 6	406	The authors would like to acknowledge Alice Craven and Dr. Glyn Burtt for supporting the
7 8	407	manuscript development.
9 10 11	408	FUNDING STATEMENT
12 13 14	409	This study was supported by funding from Boston Scientific. Coreva Scientific GmbH & Co KG
14 15 16	410	received consultancy fees from Boston Scientific for work related to this manuscript. SJ, AT,
17 18	411	AE, AB, PD, CP, and HP were contracted for this study and reimbursed at fair, local market
19 20	412	rates for their time commitment during the Delphi process but received no reimbursement for
21 22	413	their participation in the manuscript development.
23 24 25	414	
26 27	415	RS is the owner of Coreva Scientific, a health-economics and value-based healthcare
28 29	416	consultancy that focuses on medical devices. AHH is an employee of Coreva Scientific.
30 31 32	417	Coreva Scientific received consultancy fees from Boston Scientific for work related to this
32 33 34	418	manuscript. The authors did not receive direct payment as a result of this work outside of their
35 36	419	normal salary payments. EW is an employee of Boston Scientific.
37 38 39	420	AUTHOR CONTRIBUTIONS
40 41	421	EW conceptualised the idea. RS and AHH designed and ran the questionnaires and
42 43	422	implemented data protection measures. EW reviewed the study design. AHH and RS analysed
44 45	423	the responses. RS moderated the advisory boards. SJ, AT, AE, AB, PD, CP, and HP
46 47	424	responded to the questionnaires, and participated in the advisory boards. AHH and RS drafted
48 49	425	the manuscript, in collaboration with SJ, AT, AE, AB, PD, CP and HP. All authors critically
50 51	426	reviewed the manuscript outline and manuscript drafts. All authors approved the final
52 53 54 55 56 57	427	manuscript.
58 59 60		

428 ETHICS APPROVAL STATEMENT

- 429 The study was approved by an independent review board (HML IRB Review #952SCGC21).
- 430 All participants gave informed consent before taking part.

11 431 DATA SHARING STATEMENT

432 No additional data available.

16 433 LEAD AUTHOR TRANSPARENCY STATEMENT

434 I confirm that the manuscript is an honest, accurate, and transparent account of the study
435 being reported; that no important aspects of the study have been omitted; and that any
436 discrepancies from the study as originally planned have been explained.

437 Prof. Heather Ann Payne

REFERENCES

- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660 [published Online First: 2021/02/05]
- 2. Cancer Research UK. Prostate cancer statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero accessed 2021-11-23.
- 3. Prostate cancer UK. Prostate information. About prostate cancer 2019 [Available from: https://prostatecanceruk.org/prostate-information/about-prostate-cancer accessed 2021-11-23.
- 4. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375(15):1415-24. doi: 10.1056/NEJMoa1606220 [published Online] First: 2016/09/15]
- 5. Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer 2020;129:41-49. doi: 10.1016/j.ejca.2020.01.011 [published Online First: 2020/03/03]
- 6. Nazim SM, Fawzy M, Bach C, et al. Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer. Arab J Urol 2018;16(4):367-77. doi: 10.1016/j.aju.2018.06.008 [published] Online First: 2018/12/121
- 7. Cancer Research UK. Prostate cancer treatment statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/diagnosis-and-treatment accessed 2021-10-26.
- 8. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management NICE guideline Published: 9 May 2019 2019.
- 9. Moris L, Cumberbatch MG, Van den Broeck T, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77(5):614-27. doi: 10.1016/j.eururo.2020.01.033 [published Online First: 2020/03/09]
- 10. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79(2):243-62. doi: 10.1016/j.eururo.2020.09.042 [published Online First: 2020/11/121
- 11. National Prostate Cancer Audit (NPCA). Annual Report 2020 Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019 (published January 2021)., 2021.
- Where 12. Prostate Matters. to access SBRT [Available from: https://prostatematters.co.uk/prostate-cancer/where-to-access-sbrt/ accessed 2021-11-26.

13. Miller LE, Efstathiou JA, Bhattacharyya SK, et al. Association of the

1 2 3

4

483

Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of 484 5 Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review 485 6 7 Meta-analysis. JAMA Netw Open 2020;3(6):e208221. 486 and doi: 8 10.1001/jamanetworkopen.2020.8221 [published Online First: 487 9 488 2020/06/26] 10 489 14. National Prostate Cancer Audit (NPCA). Annual Report 2020 Methodology 11 12 supplement, 2021. 490 13 15. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally 491 14 492 fractionated radiotherapy for patients with prostate cancer (HYPRO): late 15 493 toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet 16 2016;17(4):464-74. doi: 10.1016/s1470-2045(15)00567-7 17 494 Oncol 18 495 [published Online First: 20160309] 19 16. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An Analysis of 496 20 497 Treatment-Related Morbidity for a Randomized Trial Comparing a Low-21 22 498 Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam 23 499 Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat 24 Oncol Biol Phys 2017;98(2):286-95. doi: 10.1016/j.ijrobp.2017.01.008 500 25 501 [published Online First: 20170106] 26 27 502 17. Ardekani MA, Ghaffari H. Optimization of prostate brachytherapy 28 techniques with polyethylene glycol-based hydrogel spacers: a 503 29 504 systematic review. Brachytherapy 2020;19(1):13-23. 30 Health Care 505 18. National Institute for and Excellence (NICE). 31 INTERVENTIONAL PROCEDURES PROGRAMME Equality impact 32 506 33 507 assessment IPG590 Biodegradable spacer insertion to reduce rectal 34 toxicity during radiotherapy for prostate cancer, 2016. 508 35 19. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective 509 36 Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical 510 37 38 of Perirectal Spacer Application in 511 Effects Men Undergoing 39 Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 512 40 513 Radiat Oncol Biol Phys 2015;92(5):971-77. doi: 41 10.1016/j.jirobp.2015.04.030 [published Online First: 20150423] 514 42 43 20. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal 515 44 Separation for Prostate Radiation Therapy: Final Results of a Phase III 516 45 Radiat Oncol Biol Phys 2017;97(5):976-85. 517 Trial. Int J doi: 46 10.1016/j.ijrobp.2016.12.024 [published Online First: 2017/02/18] 518 47 48 21. Quinn TJ, Daignault-Newton S, Bosch W, et al. Who Benefits From a 519 49 Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract 520 50 Radiat Oncol 2020;10(3):186-94. doi: 10.1016/j.prro.2019.12.011 521 51 [published Online First: 2020/01/25] 522 52 53 22. Keeney S, Hasson F, McKenna H. Consulting the oracle: ten lessons from 523 54 using the Delphi technique in nursing research. Journal of advanced 524 55 nursing 2006;53(2):205-12. 525 56 23. Keeney S, McKenna H, Hasson F. The Delphi technique in nursing and 526 57 58 health research: John Wiley & Sons 2011. 527 59 60

24. Courtenay M, Deslandes R, Harries-Huntley G, et al. Classic e-Delphi

survey to provide national consensus and establish priorities with regards to the factors that promote the implementation and continued development of non-medical prescribing within health services in Wales. BMJ Open 2018;8(9):e024161. doi: 10.1136/bmjopen-2018-024161 [published Online First: 2018/09/21] 25. Howarth E, Vainre M, Humphrey A, et al. Delphi study to identify key features of community-based child and adolescent mental health services in the East of England. BMJ Open 2019;9(6):e022936. doi: 10.1136/bmjopen-2018-022936 [published Online First: 2019/06/22] 26. Snape D, Kirkham J, Preston J, et al. Exploring areas of consensus and conflict around values underpinning public involvement in health and social care research: а modified Delphi study. BMJ Open 2014;4(1):e004217. doi: 10.1136/bmjopen-2013-004217 [published Online First: 2014/01/15] 27. Taylor RM, Feltbower RG, Aslam N, et al. Modified international e-Delphi survey to define healthcare professional competencies for working with teenagers and young adults with cancer. BMJ Open 2016;6(5):e011361. doi: 10.1136/bmjopen-2016-011361 [published Online First: 2016/05/05] 28. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67(4):401-9. doi: 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04] 29. General Medical Council (GMC). Good medical practice 2019 [Available from: https://www.gmc-uk.org/-/media/documents/good-medical-practice---english-20200128 pdf-51527435.pdf. 30. Suneil Jain (Principal investigator). NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy (SABRE) 2021 [Available from: https://clinicaltrials.gov/ct2/show/NCT04905069?term=spaceoar&draw= 2&rank=1. 31. Vanneste BG, Hoffmann AL, van Lin EN, et al. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiother Oncol 2016;121(1):118-23. doi: 10.1016/j.radonc.2016.08.026 [published Online First: 20160916] 32. Vanneste BGL, Van Limbergen EJ, Marcelissen T, et al. Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? Clin Transl Radiat Oncol 2021;27:121-25. doi: 10.1016/j.ctro.2021.01.007 [published Online First: 20210125] 33. Vanneste BGL, Van Limbergen EJ, van de Beek K, et al. A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn's disease. Tech Innov Patient Support Radiat Oncol 2018;6:1-4. doi: 10.1016/j.tipsro.2018.01.004 [published Online First: 20180320] Page 24 of 25

- 34. Hutchinson RC, Sundaram V, Folkert M, et al. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. Urol 2016;34(7):291.e19-26. doi: 10.1016/j.urolonc.2016.02.024 Oncol [published Online First: 20160330]
- 957935. Levy JF, Khairnar R, Louie AV, et al. Evaluating the Cost-Effectiveness of11580Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. Pract12581Radiat Oncol 2019;9(2):e172-e79. doi: 10.1016/j.prro.2018.10.00313582[published Online First: 20181017]14582San Dalate Cancer Radiation Therapy. Pract
- 36. Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et al. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? Radiother Oncol 2015;114(2):276-81. doi: 10.1016/j.radonc.2015.01.005 [published Online First: 20150120]
- ²⁰ 587 Figure legends


²³ 24 588 **FIGURE 2**:


Strong consensus could only be reached if all experts indicated that they "Fully agree" or all except one "Fully agree", with the last respondent "Partially agree" with only a minor word change (score ≥27). Moderate consensus could only be reached if at least five respondents "Fully agree", and with no "Disagree". Weak consensus was reached where a maximum of three respondents "Partially agree", and with no "Disagree". No consensus was indicated where at least one respondent "Disagree", or if four or more respondents "Partially agree".


³⁹₄₀ 595 **FIGURE 4**:

596 Key: BT, brachytherapy; LDR, low dose rate; HDR, high dose rate; PBT, proton beam therapy,

- 597 IMRT, intensity-modulated radiation therapy; IGRT, image guided radiation therapy, SBRT,
- 598 stereotactic body radiation therapy; SABR, stereotactic ablative radiotherapy







1 2												
- 3 4	BT monotherapy (LDR)		1				I		67			
5 6	BT monotherapy (HDR)									72		
7	PBT								,	75		
8 9												
10	BT boost									76		
11 12	IMRT/IGRT: 74 Gy in 37 fx (2 Gy per fx)									78		
13 14	IMRT/IGRT: 60 Gy in 20 fx (3 Gy per fx)									79		
15	SBRT/SABR									80)	
16 17		0	10	20	30	40	50	60	70	80	90	100
18												
19 20												
21												
22 23												
24 25												
26												
27 28												
29												
30 31												
32 33												
34												
35 36												
37												
38 39												
40												
41 42												
43 44												
45												
46 47												
48												
49 50												
51												
52 53												
54												
55 56												
57												
58 59												
60												



Wolters Kluwer Thank You This PowerPoint document contains the images that you requested. ght Notice regials on this Site are protected by United States copyright law and may not be reproduction

Copyright Notice

All materials on this Site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Wolters Kluwer. You may not alter or remove any trademark, copyright or other notice. $\frac{4}{57}$

However, provided that you maintain all copyright, trademark and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only. Please refer to this link for further information on how to apply for permission for re-use


Any information posted to discussion forums (moderated and un-moderated) is for informational purposes only. We are not responsible for the information or the result of its practice.



1	
2	
3	
4	
5	
6	
7	
8	
9	
1	0
1	1
' 1 1 1	2
1	3
1	4
	5
1	6
1	7
1	8
1	9
	0
2	1
2	2
2	
2	4
2	5
2	6 7 8
2	7
2	8
2	9
3	0
3	1
3	
3	3
3	
3	
- 3	6
_	_
3	7
3	6 7 8
3	9
3 4	7 8 9 0

Wolters Kluwer

	Title and abstract	
\$1	Title	Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g., athnography, grounded theory) or data collection methods (e.g., interview, focus group) is recommended
52	Abstract	Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results, and conclusions
	Introduction	
53	Problem formulation	Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement
\$4	Purpose or research question	Purpose of the study and specific objectives or questions
	Methods	
55	Qualitative approach and research paradigm	Qualitative approach (e.g., ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g., postpositivist, constructivist/ interpretrivist) is also recommended; rationale*
56	Researcher characteristics and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualification/lexperience, relationship with participants, assumptions, and/or presoppositions, potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results, and/or transferability
57	Contest	Setting/site and salient contextual factors; rationale ⁶
58	Sampling strategy	How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g., sampling saturation); rationale ⁶
59	Ethical issues pertaining to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues
510	Data collection methods	Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in response to evolving study findings; rationale ⁶
\$11	Data collection instruments and technologies	Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; it/how the instrument(s) changed over the course of the study
\$12	Units of study	Number and relevant characteristics of participants, documents, or events included in the study, level of participation (could be reported in results)
\$13	Data processing	Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/deidentification of excerpts
\$14	Data analysis	Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale *
\$15	Techniques to enhance trustworthiness	Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale ^b
	Results/findings	
516	Synthesis and interpretation	Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory.
\$17	Links to empirical data	Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings
	Discussion	
518	Integration with prior work, implications, transferability, and contribution(s) to the field	Short summary of main findings, explanation of how findings and conclusions connect to, support, ebiborate on, or challenge condusions of aedier scholaship; discussion of scope of application/ generalizability; identification of unique contribution(s) to scholarship in a discipline or field
\$19	Limitations	Trustworthiness and limitations of findings
	Other	
\$20	Conflicts of interest	Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed
521	Funding	Sources of funding and other support; role of funders in data collection, interpretation, and reporting
critical apprais contacting ex research by p The nationale : rather than of	nated the SRQR by searching the literature to identify guidelines, re all criterie for qualitative research; eventries the reference liths of in perits to gain feedback. The SRQR list into to reprove the transparence, though being thousan the puritication for choosing that theory, appr their options available, the assumptions and limitations implicit in the nex study conclusions and shartheability. As appropriate, the relation	trieved ources; and of all aspects of qualitative pack, method, or technique se choices, and how those



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Copyright © 2022 by the Association of American Medical Colleges